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Background: Much of the research literature in the hEDS and HSD populations focuses on 
diagnostic classification and quantifying patients’ physical and psychological functioning. Little 
is known about the psychological processes and outcomes of individuals living with these 
illnesses.  
Objective: Our study aims to explore factors related to illness identity and psychological 
adaptation in individuals with hEDS or HSD.   
Methods: We distributed an online survey through the EDS Society to adults with hEDS or 
HSD.  
Results: Overall, 399 individuals participated in our study. Participants viewed their illness as 
threatening, perceived moderate uncertainty, had moderate confidence in their coping ability, 
moderate anxiety, mild depression, and moderate adaptation. Higher rejection identity was 
significantly correlated with lower number of illness characteristics, greater perceived impact of 
illness characteristics, more threatening illness perceptions, and more uncertainty. In regression 
analysis, individuals who felt threatened by and uncertain about their illness were significantly 
more likely to reject their illness as part of their identity. Higher acceptance identity was 
significantly correlated with less uncertainty and less coping self-efficacy. In regression analysis, 
individuals who had higher coping self-efficacy were less likely to accept their illness as part of 
their identity. Higher engulfment identity was significantly correlated with higher number of 
illness characteristics, less perceived impact of illness characteristics, less threatening illness 
perceptions, more uncertainty, and more coping self-efficacy. In regression analysis, individuals 
who viewed their illness as uncertain and had higher coping self-efficacy were more likely to 
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become engulfed by their illness. Additionally, individuals who perceived their illness as 
threatening were less likely to become engulfed by their illness. Higher enrichment identity was  
correlated with more threatening illness perceptions and less coping self-efficacy. In regression 
analysis, individuals with higher coping self-efficacy were less likely to be enriched by their 
illness.   
Discussion: Further research is needed to understand the unexpected relationships among the 
illness identity states, coping self-efficacy, and emotional distress. Our study contributes to better 
understanding of illness identity and psychological adaptation in individuals with hEDS or HSD. 
This may allow genetic counselors to better care for their patients and potentially provide 
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Current Research on hEDS and HSD 
Description & Diagnosis 
Despite being the one of the most common heritable connective tissue disorders, accurate 
recognition and diagnosis of Hypermobile Ehlers Danlos syndrome (EDS Hypermobility type or 
hEDS) remains an ongoing challenge1-8. Often, hEDS is used as a “default” diagnosis to explain 
individuals with chronic pain and generalized joint hypermobility when other conditions have 
been ruled out3, 6, 9, 10. Generalized joint hypermobility is a non-specific feature of many 
connective and non-connective tissue disorders, therefore a diagnosis of hEDS must also include 
multiple systemic connective tissue findings2, 5, 11. Sleep disturbance, fatigue, postural orthostatic 
tachycardia syndrome (POTS), functional gastrointestinal disorders, dysautonomia, anxiety, and 
depression have all been associated with but are non-specific to hEDS2, 7, 10, 11. Additionally, 
variability in clinical features is substantial which makes it difficult to distinguish between 
conditions and predict prognosis.  
Molecular confirmation is available for most types of Ehlers Danlos Syndrome (EDS) 
and other connective tissue disorders, however definitive causative genes are unknown for the 
vast majority of individuals with hEDS. Diagnosis of hEDS is based solely on clinical diagnostic 
criteria2, 4. In 2017, Malfait and other experts revised and purposefully made more stringent, the 
diagnostic criteria for hEDS in an effort to reduce heterogeneity with hopes to better facilitate 
gene discovery2. Individuals not meeting criteria for hEDS are given the diagnostic label of 
Hypermobility Spectrum Disorder (HSD)1, 4. Both hEDS and HSD lie on a continuum of 
conditions featuring joint hypermobility and clinical management is the same regardless of the 
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diagnosis1. However, identification of an underlying genetic cause(s) is valuable for molecular 
confirmation and distinction from other conditions featuring joint hypermobility. Patients’ 
perceptions of uncertainty in their diagnosis and their ability to cope with these uncertainties 
have yet to be explored in the research literature in the hEDS and HSD populations.  
Illness Chronicity & Impact 
While there is a phenotypic spectrum, hEDS and HSD have been associated with 
musculoskeletal and non-musculoskeletal problems, which vary in extent, severity, and pain2, 7, 
11, 12. Chronic pain and fatigue are prevalent problems and have a significant impact on physical, 
emotional/psychological, and social functioning in individuals with hEDS or HSD7-9, 13-22. A 
qualitative interview study of individuals with EDS explored their experiences living with pain; 
many of them explaining the constant nature of their pain, “learning” to live with pain and being 
limited in their educational pursuits, job opportunities, and social activities19. In addition to the 
significant impact on physical and psychological functioning, chronic pain and fatigue have the 
potential to become disabling. Baeza-Velasco and colleagues reviewed 33 studies examining the 
psychological factors related to chronic pain and disability in individuals with hEDS9.  Chronic 
pain and fatigue were associated with reduction in cognitive abilities, increased somatosensory 
amplification and pain catastrophizing, high levels of negative emotions, symptoms of anxiety 
and depression, and fluctuations in activity levels leading to hypervigilant or avoidant 
behaviors9. These cognitive, emotional, and behavioral aspects contribute to overall 
psychological functioning in individuals with hEDS or HSD.  
The biopsychosocial model of health explains the bidirectional relationship between 
physical and psychological functioning. In a retrospective chart review study, Hershenfeld and 
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colleagues identified mental health concerns in just less than half (42.5%) of individuals with 
hEDS or HSD, the most common being anxiety and depression23. In response to the significant 
psychological impact of living with hEDS or HSD, a few studies have investigated the use of 
psychotherapeutic interventions such as Cognitive-Behavioral Therapy (CBT). Positive 
outcomes were observed with reduction in anxiety, depression, catastrophizing, and an 
improvement in self-efficacy9, 24, however, these studies have small sample sizes and are limited 
in generalizability. While there is strong evidence for the relationship between chronic pain and 
fatigue with physical and psychological functioning, there is little research exploring patients’ 
perspectives on their illness and its effect on their identity and life.   
Conceptual Framework 
 The conceptual framework for our study drew from several different theories with the 
aim to explore illness identity and psychological adaptation in individuals with hEDS or HSD 
[see FIGURE 1]. The foundation for this framework builds from Lazarus and Folkman’s 
Transactional Model of Stress and Coping (TMSC)25, 26 and the Common Sense Model of 
SelfRegulation (CSM) by Leventhal and colleagues27, 28. A chronic illness such as hEDS or 
HSD, threatens the body and disrupts an individual’s sense of self29. Stress is the result of the 
interaction between an individual (their physiological, cognitive, affective, and psychological 
selves) and their environment25, 26. A chronic illness is a source of stress25, 26, 29. The relationship 
between stress and the environment can be explained by the processes of cognitive appraisals 
and coping25-28. An individual’s evaluation of the relevance or risk of a stressor to themselves is 
known as primary appraisal. A stressor can either be appraised as a threat to self or as an 
opportunity for growth. An individual’s evaluation of their resources to deal with stress is known 
as secondary appraisal. Individuals utilize various internal and external resources such as coping 
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strategies and social support to deal with stress 25, 26. Selection of coping strategies is directed by 
individuals’ appraisals of stress. Being able to effectively cope with stress benefits various health 
and psychological outcomes25, 26. The TMSC and CSM are valuable models to use in the study of 
patient populations as appraisals, coping, and behaviors are mutable and therefore appropriate 
targets of interventions to improve health and psychological outcomes of patients. Our research 
study aims to assess relationships among various types of appraisals and outcomes to understand 
how individuals integrate their illness into their identity and adapt to living with hEDS or HSD..  
Appraisals 
The constructs used in our research study to capture the appraisal process consist of 
Illness Perceptions, Uncertainty in Illness, and Coping Self-Efficacy [see FIGURE 1]. The 
construct of Illness Perceptions, from Leventhal’s CSM, assesses individuals’ cognitive and 
emotion representations of an illness27, 30, 31. The five attributes of illness perceptions include 1) 
identity of the disease (ie. symptoms, labels), 2) timeline (ie. onset, duration, recovery time), 3) 
perceived cause(s) (ie. germs, genetic variants), 4) consequences (ie. death, disability, pain, 
social and economic loss), and 5) controllability (ie. intractable vs. susceptible to self-treatment, 
medication, surgery)30, 31. Primary appraisals focus on the nature of the stressor therefore the 
construct of Illness Perceptions can be used to assess how individuals with hEDS or HSD 
perceive their illness.  One study by Hope and colleagues found that individuals with hEDS or 
HSD perceived their illness to be complex and chronic32. Affected individuals felt they had 
moderate personal and treatment control over their illness32. This study provides insight into 
individuals’ perceptions of living with hEDS or HSD yet the researchers do not relate these 
perceptions to either health or psychological outcomes. To potentially target illness perceptions 
through interventions, it is first necessary to understand its relationship with measurable 
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outcomes. Our study evaluates the relationships among illness perceptions and two primary 
outcomes: illness identity and psychological adaptation [see FIGURE 1]. In addition to illness 
perceptions, individuals with hEDS or HSD may perceive uncertainty in their illness due to the 
erratic nature of symptomatology and ambiguity in symptoms and diagnosis33. Individuals with 
hEDS or HSD may experience multiple levels of uncertainty in the cause, prognosis, 
consequences, outcomes, and meaning of their illness33-37.  Uncertainty has the ability to invade 
one’s ability to cope and adapt to living with an illness34-36.  The construct of Uncertainty in 
Illness, from Mishel’s Uncertainty in Illness theory, assesses individuals’ perceptions of 
uncertainty in illness34-36. Secondary appraisals focus on the abilities and resources of individuals 
to deal with a stressor therefore the construct of Uncertainty in Illness can be used to assess 
perceptions of uncertainty in individuals with hEDS or HSD. Although uncertainty likely 
contributes to many challenges faced by individuals with hEDS or HSD, it has not previously 
been quantifiably studied. Our study evaluates the relationships among uncertainty in illness and 
two primary outcomes: illness identity and psychological adaptation [see FIGURE 1].  
Due to symptoms, comorbidities, and other challenges of living with hEDS or HSD, 
affected individuals may utilize a variety of cognitive and behavioral efforts to deal with their 
illness. Hypervigilance or avoidance are common behaviors of affected individuals when seeking 
medical care and management however both are associated with poor outcomes that can 
potentially lead to disability9. Little is known about the coping strategies and behaviors utilized 
by individuals with hEDS or HSD and the effect of these efforts on health and psychological 
outcomes. Being able to cope effectively to stress or a health threat leads to positive outcomes as 
demonstrated by Lazarus’ TMSC25, 26. The construct of Coping Self-Efficacy assesses an 
individual’s confidence in their ability to cope effectively38. Secondary appraisals focus on the 
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abilities and resources of individuals to deal with a stressor therefore the construct of Coping 
Self-Efficacy can be used to assess confidence in coping of individuals with hEDS or HSD. Our 
study evaluates the relationships among coping self-efficacy and two primary outcomes: illness 
identity and psychological adaptation [see FIGURE 1]. 
Illness Identity  
“Chronic illness assaults the body and threatens the integrity of self”29. From bodily 
losses to loss of relationships, individuals with chronic illness repeatedly experience loss29. In 
response to loss, individuals question and redefine their identities29. According to Erikson, 
identity refers to the degree to which individuals integrate personality, social interactions, and 
life experiences into a coherent sense of self which guides values and behaviors39. A chronic 
illness interferes with identity formation and creates tension between body and self. According to 
Charmaz’s theory on Body, Identity, and Self, there are a variety of ways individuals manage the 
tension between body and self: some ignore, minimize, or struggle against their illness whereas 
others reconcile, surrender or embrace their illness29. Successful adaptation occurs when 
individuals are able to live with their illness and are not be defined by it, resulting in optimal 
physical and psychological functioning29. Individuals with hEDS or HSD feel they are “living a 
restricted life” due to living in fear, living with pain, feeling stigmatized, experiencing lack of 
affirmation from the healthcare community, and feeling limited in education, career 
opportunities, and social activities19. All of these challenges may contribute to tension between 
body and self when living with a chronic condition therefore interfering with physical and 
psychological functioning.   
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Little is known about how individuals with hEDS or HSD incorporate their illness into their 
identity, what factors influence illness identity, and how illness identity affects health and 
psychological outcomes. Our research study uses the construct of Illness Identity to capture  how 
illness influences sense of self and the degree to which it is included in identity formation29, 40, 41. 
The construct of Illness Identity includes 4 different states: rejection, engulfment, acceptance, 
and enrichment.   Rejection, or the degree to which an illness is rejected as part of one’s identity, 
and engulfment, or the degree to which an illness dominates one’s identity capture negative 
illness identities or less adaptive forms of illness integration40, 41. Acceptance, or the degree to 
which an illness is accepted as part of one’s identity, and enrichment, or the degree to which an 
illness positively affects one’s identity, capture positive illness identities or more adaptive illness 
integration40, 41. The construct of Illness Identity has been evaluated in a few populations 
including adolescents and emerging adults with type 1 diabetes40, adults with chronic illness42, 
young adults with refractory epilepsy43, and adults with congenital heart disease44. These studies 
demonstrated differentiation among the 4 illness identity states. Additionally, these studies 
showed that the degree to which an illness is integrated into a one’s identity is associated with 
physical and psychological functioning as well as behavioral outcomes such as treatment 
adherence and healthcare utilization 40-42, 44, 45. Our study evaluates the relationships among 
illness perceptions, uncertainty in illness, coping self-efficacy and the outcome of illness identity 
in individuals with hEDS or HSD [see FIGURE 1]. Also, our study evaluates the relationships 
between the outcomes of illness identity, emotional distress, and psychological adaptation [see 




 Individuals’ ability to effectively manage their illness and its potential stress is known as 
psychological adaptation. Adaptation is more than just optimal physical functioning and 
psychological well-being. According to Lazarus’ TMSC25, 26, adaptation is the outcome of 
appraising stressors or health threats and using coping strategies effectively. However, 
adaptation can also be viewed as a process. According to Taylor’s Theory of Cognitive 
Adaptation (TCA)46, searching for meaning, regaining control, and rebuilding self-esteem is the 
process of adaptation. This ongoing process fluctuates throughout life and with different 
stressors46. However, many individuals are able to find restoration and hopefulness through the 
process of adaptation46, 47. The construct of Psychological Adaptation assesses how individuals 
adapt to a chronic condition48. Biesecker and Erby suggest that successful coping, restored self-
esteem, spiritual and psychological well-being, and social integration are all indicators of a well-
adapted individual48, 49. Individuals with hEDS or HSD experience many physical7, 11, 12, 17, 
psychological9, 22, and social challenges19, 50 and little is known about their adaptation to living 
with a chronic illness. .  Our study evaluates the relationships among illness perceptions, 
uncertainty in illness, coping self-efficacy and the outcome of psychological adaptation in 
individuals with hEDS or HSD [see FIGURE 1]. Also, our study evaluates the relationships 
























Much of the research literature in the hEDS and HSD populations focuses on the 
description and diagnosis of these conditions, patients’ experiences of illness chronicity, and its 
effect on physical and psychological functioning. Affected individuals have chronic pain and 
fatigue among other co-morbidities that contribute to the chronic and complex nature of hEDS 
and HSD. Additionally, they experience challenges including uncertainty in diagnosis, lack of 
access to knowledgeable healthcare providers, limited treatment and management options, and 
potential for substantial disability. As a result of these comorbidities and challenges, physical 
and psychological functioning is negatively affected in these individuals. Further research is 
needed to explore how affected individuals perceive their illness, appraise uncertainty and their 
ability to cope, integrate their illness into their identity, and adapt to living with a chronic illness. 
The objectives of our study are to contribute to a greater understanding of how these concepts 
interact with each other and provide insight into the perspectives and needs of patients with 
hEDS or HSD which may allow genetic counselors to provide better clinical care for individuals 











OBJECTIVE AND SPECIFIC AIMS 
Much of the research literature in the hEDS and HSD populations has concentrated on 
two main topics: diagnosis and illness chronicity. Individuals experience challenges regarding 
uncertainty in diagnosis51, lack of access to knowledgeable healthcare providers51-53, limited 
treatment and management options51-53, and potential for substantial disability15. Further 
exploration of these challenges is warranted to understand if and how individuals incorporate 
their illness into their identity and adapt to living with hEDS or HSD.  
Aim 1: To examine the relationships between predictors [diagnosis and illness characteristics 
and primary and secondary appraisals] and outcome of illness identity. 
*In our study, primary appraisals is captured by a measure of illness perceptions and secondary 
appraisals is captured by measures of uncertainty in illness and coping self-efficacy.  
Hypothesis: Individuals with greater number and impact of symptoms, greater perceptions of 
their illness as threatening, greater uncertainty in their illness, and lower coping self-efficacy will 
have higher scores in the rejection or engulfment identities.  
Aim 2: To examine relationships between illness identity and outcomes of emotional distress 
and psychological adaptation.  
*In our study, emotional distress is captured by measures of anxiety and depression.  
Hypothesis: Individuals who have higher scores in the rejection or engulfment identities will 






Study Design  
Our cross-sectional study used an online survey to examine illness identity and 
psychological adaptation in individuals with hEDS or HSD. Potential participants for the main 
study were recruited from the Ehlers Danlos Society (EDS Society) [see APPENDIX 1]. The 
EDS Society posted the link to the survey in the research section on their website and on 
Instagram. Participants completed an online survey consisting of several validated measures of 
concepts from within the conceptual framework. The survey was developed using the survey 
software, Qualtrics. Estimated time to complete the survey was 30-40 minutes. Participants who 
completed the survey were eligible to receive a $5.00 electronic gift card.  
Pilot Study 
A pilot study was conducted before the main study was distributed. The purpose of the 
pilot study was to ensure that the questions and instructions on the survey were clear to 
participants. Pilot participants were asked to complete the survey and provide feedback by 
responding with any questions or comments about the survey. Participants for the pilot study 
were recruited from the Johns Hopkins Department of Genetic Medicine. Two genetic 
counselors, Christy H. Smith, ScM, CGC and Weiyi Mu, ScM, CGC, and one geneticist, Joann 
Bodurtha, MD, MPH, invited potential pilot participants either in person during their 






The study participants were individuals with a self-reported clinical diagnosis of hEDS or 
HSD. Inclusion criteria specified individuals age 18 years or older with a clinical diagnosis of 
hEDS or HSD. Exclusion criteria specified individuals who did not have a clinical diagnosis of 
hEDS or HSD, individuals under the age of 18 years, and individuals who did not speak or 
understand written English. There were no eligibility restrictions based on demographics such as 
race, ethnicity, and sex.  
The proposed sample size for our study was 250 individuals. A power calculation for 
regression analysis was conducted to specifically assess the relationship between illness identity 
and psychological adaptation [see TABLE 1]. Holding alpha at 0.05 and power at 0.80, a small 
(r = 0.1) to medium (r = 0.3) effect size was reasonable for this study based on previous studies 
evaluating factors associated with psychological adaptation54-60 and acceptable benchmarks for 
social and behavioral science research61. This power calculation was also appropriate to use in 




















1 787 0.05 0.8 1 1 0.1 
2 198 0.05 0.8 1 1 0.2 
3 89 0.05 0.8 1 1 0.3 
4 51 0.05 0.8 1 1 0.4 
5 33 0.05 0.8 1 1 0.5 
 


















Participants were asked a series of 6 single-answer questions regarding their current age, 
sex, race, ethnicity, marital status, and highest level of education. 
Diagnosis Characteristics 
Participants were asked a series of 6 single-answer questions regarding their diagnosis of 
hEDS or HSD [see APPENDIX 3]. These questions included “Have you been given a formal 
clinical diagnosis of hEDS or HSD by a healthcare provider?”, “For the healthcare provider who 
diagnosed your condition, which condition did he or she diagnose you with?”, “What other 
diagnoses have you been given in the past?”, “At what age did you first notice signs or 
symptoms of hEDS or HSD?”, “At what age were you diagnosed with hEDS or HSD?”, and 
“How much time has passed since your diagnosis of hEDS or HSD?”.  
Illness Characteristics 
Participants were provided a list of 21 symptoms/comorbidities that have been associated 
with hEDS or HSD [see APPENDIX 3]. This list was developed for our specific study. 
Symptoms/co-morbidities were selected based on the clinical diagnostic criteria2, the research 
literature8, 11, 12, 21, 62, and in consultation with geneticist, Dr. Joann Bodurtha, and genetic 
counselor, Christy H. Smith. Participants were asked if they experienced the symptom/co-
morbidity (0 = “No” and 1 = “Yes”) and its degree of impact on their health by responding to a 
5-point Likert scale (1 = “strongly disagree” to 5 = “strongly agree”). The score for each 
symptom/comorbidity was simply the response to the question. An overall score was calculated 
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for total count of illness characteristics and total impact of illness characteristics by adding each 
response respectively. A higher score for total count of illness characteristics reflects a high 
amount of symptoms/comorbidities experiences whereas a lower score reflects a lower amount 
of symptoms/comorbidities experiences. A higher score for total impact of illness characteristics 
reflects a greater perceived impact of symptoms/comorbidities whereas a lower score reflects a 
lesser perceived impact of symptoms/comorbidities.  
Illness Perceptions  
Participants were asked a series of 9 questions through a previously validated scale, 
Illness Perceptions Questionnaire-Brief Form (IPQ-B)31, to assess participants’ perceptions of 
living with hEDS or HSD. Each question corresponds to a specific dimension of the IPQ-B scale 
assessing participants cognitive and emotional representations of living with their illness [see 
APPENDIX 3]. These dimensions consist of (1) Consequences, (2) Timeline, (3) Personal 
Control, (4) Treatment Control, (5) Identity, (6) Concern, (7) Coherence, (8) Emotional 
Representations, and (9) Causes. Participants were asked to respond to each question (except 
Causes) on an 11-point Likert scale. An example of a survey question is “How much control do 
you feel you have over your illness?” (Dimension: Personal Control). For the Causes question, 
participants were asked to list in rank order the 3 most important factors that they believe caused 
their illness. The score for each dimension (except Causes) is simply the response to the 
question. An overall score was calculated by reverse scoring questions 3, 4, and 7 and adding 
them to questions 1, 2, 5, 6, and 8. A higher score reflects a more threatening view of the illness 
whereas a lower score reflects a more benign view. For the causes question, responses were 
grouped into categories based on thematic content analysis. Internal reliability (Cronbach’s 
alpha) of the IPQ scale has been reported to range from 0.702 to 0.720 in published research 
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literature59, 63, 64. A systematic review and meta-analysis of 188 studies, found good concurrent 
and predictive validity65.  
Uncertainty in Illness  
Participants were asked a series of 22 questions through a previously validated scale, 
Mishel Uncertainty in Illness Scale-Community Form (MUIS-C)36, to assess participants 
perceived uncertainty in their hEDS or HSD. The first 14 questions correspond to the dimension 
of Ambiguity/Future Uncertainty whereas the last 8 questions correspond to the dimension of 
Unpredictability [see APPENDIX 3]. Participants were asked to respond to each question on a 
5-point Likert scale (1 = “strongly disagree” to 5 = “strongly agree”). An example of a survey 
question is “I have a lot of questions without answers” (Dimension: Ambiguity/Future 
Uncertainty). The score for the Ambiguity/Future Uncertainty dimension was calculated by 
adding the responses to each question. The score for the Unpredictability dimension was 
calculated by reverse scoring all questions and then adding them together. An overall scale score 
was calculated by adding the 2 dimension scores. A higher score reflects greater perceived 
uncertainty in illness whereas a lower score reflects less perceived uncertainty. Internal 
reliability (Cronbach’s alpha) of the MUIS scale has been reported to range from 0.71 to 0.91 in 
the published research literature66.  
Coping Self-Efficacy  
Participants were asked a series of 13 questions through a previously validated scale, 
Coping Self-Efficacy (CSE)38, to assess participants confidence in their ability to cope 
effectively. The first 6 questions correspond to the dimension of Use of Problem-Focused 
Coping, the next 4 questions correspond to the dimension of Stopping Unpleasant Emotions and 
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Thoughts, and the last 3 questions correspond to the dimension of Getting Support from Friends 
and Family [see APPENDIX 3]. Participants were asked to respond to each question on an 11-
point Likert scale (1 = “cannot do at all” to 11 = “certainly can do”). An example of a survey 
question is “Break an upsetting problem down into smaller parts” (Dimension: Use of Problem-
Focused Coping). The score for each dimension was calculated by averaging the responses to 
each question. An overall scale score was calculated by averaging the 3 dimension scores. A 
higher score reflects greater confidence in their ability to effectively cope whereas a lower score 
reflects less confidence in their coping ability. Internal reliability (Cronbach’s alpha) of the CSE 
scale has been reported to range from 0.88 to 0.97 in the published research literature38, 58, 67. 
Illness Identity 
Participants were asked a series of 25 questions through a validated scale, Illness Identity 
Questionnaire (IIQ)40, to assess the degree to which they integrate hEDS or HSD into their 
identity. The construct of Illness Identity includes 4 different states: rejection, engulfment, 
acceptance, and enrichment. The first 5 questions capture the illness identity state of Rejection or 
the degree to which an illness is rejected as part of one’s identity. The next 5 questions capture 
the illness identity state of Acceptance or the degree to which an illness is accepted as part of 
one’s identity  The next 8 questions capture the illness identity state of Engulfment or the degree 
to which an illness dominates one’s identity The last 7 questions capture the illness identity state 
of Enrichment, or the degree to which an illness positively affects one’s identity [see 
APPENDIX 3]. Participants were asked to respond to each question on a 5-point Likert scale (1 
= “strongly disagree” to 5 = “strongly agree”). Examples of survey questions are “I refuse to see 
my illness as part of myself” (State: Rejection), “My illness is a part of who I am” (State: 
Acceptance), “My illness dominates my life” (State: Engulfment), and “Because of my illness, I 
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have grown as a person” (State: Enrichment).The score for each illness identity state was 
calculated by averaging the responses to each question. A higher score on any of the illness 
identity states reflects support for that illness identity state whereas a lower score reflects lack of 
support for that illness identity state. The dimensions of the IIQ demonstrate good internal 
reliability (Cronbach’s alpha) in the published research literature [Rejection (range from 0.75 to 
0.84), Acceptance (range from 0.81 to 0.85), Engulfment (range from 0.90 to 0.92), Enrichment 
(range from 0.90 to 0.95)]40-42, 44, 45. 
Emotional Distress 
Participants were asked a series of 16 questions through validated scales, PROMIS 
Anxiety-Short Form 8a (PROMIS Anx.)68 and Depression-Short Form 8a (PROMIS Dep.)68, to 
assess participants emotional distress. The first 8 questions are from the Anxiety short form and 
the last 8 questions are from the Depression short form [see APPENDIX 3]. Participants were 
asked to respond to each question on a 5-point Likert scale ( 1 = “never” to 5 = “always”). An 
example of a survey question is “My worries overwhelmed me” (Anxiety short form). The score 
for anxiety and depression for each participant is calculated through the HealthMeasures Scoring 
Service (available at http://www.healthmeasures.net/index.php) which utilizes Item Response 
Theory. PROMIS scores have a mean of 50 and standard deviation (SD) of 10 in the general 
population. A higher score reflects more symptoms of anxiety or depression whereas a lower 
score reflects less symptoms69. A development and calibration study of the PROMIS Emotional 
Distress measures demonstrated good internal consistency and validity of the Anxiety and 
Depression short forms70.  
Psychological Adaptation  
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Participants were asked a series of 20 questions through a validated scale, Psychological 
Adaptation Scale (PAS)48, to assess participants adaptation to living with hEDS or HSD. The 
first 5 questions correspond to the dimension of Coping Self-Efficacy, the next 5 questions 
correspond to the dimension of Self-Esteem, the next 5 questions correspond to the dimension of 
Social Integration, and the last 5 questions correspond to the dimension of Spiritual Well-Being 
[see APPENDIX 3]. Participants were asked to respond to each question on a 5-point Likert 
scale (1 = “strongly disagree” to 5 = “strongly agree”). An example of a survey question is 
“Helped me learn how to handle difficult times” (Dimension: Self-Esteem). The score for each 
dimension was calculated by averaging the responses to each question. An overall scale score 
was calculated by averaging the 4 dimensions scores. A higher score reflects better adaptation to 
illness whereas a lower score reflects poorer adaptation to illness. Internal reliability (Cronbach’s 
alpha) of the PAS scale has been reported to range from 0.73 to 0.97 in the published research 
literature48, 55, 56, 58-60, 71. 
Statistical Analyses  
Responses from the survey were analyzed to examine relationships between 2 main 
groups of predictors and outcomes. The first aim of our study was to examine how diagnosis and 
illness characteristics and primary and secondary appraisals are related to illness identity. In our 
study, the primary appraisal was illness perceptions and the secondary appraisals were 
uncertainty in illness and coping self-efficacy. The second aim of our study was to examine how 
illness identity related to emotional distress and psychological adaptation. In our study, 
emotional distress were symptoms of anxiety and depression. Statistical analyses were completed 




Frequencies and percentages were calculated to characterize the population based on 
demographics and diagnosis and illness characteristics. Also, means of each subscale and scale 
were calculated to characterize the population based on illness perceptions, uncertainty in illness, 
coping self-efficacy, illness identity, anxiety and depression, and psychological adaptation.  
Internal Reliability of Scales 
 Internal reliability for each of the scales used in this study was calculated by Cronbach’s 
alpha coefficients of reliability73. A Cronbach’s alpha of 0.70 or higher is considered acceptable 
(high internal reliability) in most social science research73.  
Correlation Analysis 
A Pearson pairwise correlation analysis was conducted to understand associations among 
all of our study variables except demographics and diagnosis characteristics. These variables 
included the count and impact of illness characteristics, total score for illness perceptions, total 
score for uncertainty in illness, total score for coping self-efficacy, scores for each illness identity 
state, total score for anxiety, total score for depression, and total score for psychological 
adaptation. Significant associations were determined by p < 0.05. 
Regression Analysis 
 Several multiple linear regression models were constructed to examine the associations 
between predictors and outcomes in each aim of our study. Significant associations were 
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 Of the 9 potential participants approached for the pilot survey, 2 completed the survey. 
Both individuals indicated they had a diagnosis of hEDS. The outcome of the pilot study 
consisted of only minor changes related to clarification of wording in a few questions.  
Recruitment  
Of the 591 total participants who accessed the survey, 160 participants completed less 
than 50% of the survey. Of the 431 participants who remained, 399 participants  were included in 
the study. For inclusion in statistical analyses, each participant needed to complete each measure 
used in the statistical analysis.    
Demographics 
Of the 399 participants, the majority were female (93.73%), white (93.23%), and not 
Hispanic or Latino (92.7%) [see TABLE 2]. Ages of participants included 18-25 years 
(26.57%), 26-30 years (18.05%), 31-40 years (28.07%), 41-50 years (16.29%), and greater than 
50 years (11.03%). Marital status of participants included single or never married (37.34%), 
partnered (16.29%), married (39.85%), separated or divorced (6.27%), and widowed (0.25%). 
Highest level of education of participants included less than college (16.08%), some college 





TABLE 2: Participant Demographics [N = 399]  
Category Frequency Percent 
Age     
18 - 25 years 106 26.57 
26 - 30 years 72 18.05 
31 - 40 years 112 28.07 
41 - 50 years 65 16.29 
> 50 years 44 11.03 
Sex     
Female 374 93.73 
Race     
White 372 93.23 
Ethnicity     
Not Hispanic or Latino 368 92.7 
Marital Status     
Single / Never Married 149 37.34 
Partnered 65 16.29 
Married 159 39.85 
Separated / Divorced 25 6.27 
Widowed 1 0.25 
Highest Level of Education     
< College 64 16.08 
Some College 119 29.9 
College Graduate 128 32.16 












Most participants indicated receiving a formal clinical diagnosis of hEDS or HSD by a 
healthcare provider (95.49%) and the majority were diagnosed with hEDS (79.7%) [see TABLE 
3]. Participants indicated a range of previous diagnosis including hEDS (19.73%), HSD (9.46%), 
different type of EDS (5.14%), immune deficiency or autoimmune disorder (15.14%), and other 
(50.27%). Age at onset of symptoms varied with 57.14% indicating at less than 10 years old, 
29.07% indicating at 10-18 years old, 10.53% indicating at 19-30 years old, and 3.26% 
indicating at greater than 30 years old. Age at diagnosis varied with 16.58% indicating 10-18 
years old, 40.45% indicating 19-30 years old, 24.85% indicating 31-40 years old, and 18.84% 
indicating greater than 40 years old. Amount of time since diagnosis varied with 25.31% 
indicating less than 1 year, 24.06% indicating 1-2 years, 22.81% indicating 3-5 years, 16.04% 














TABLE 3: Diagnosis Characteristics [N = 399]  
Characteristic Frequency Percent 
Formal Clinical Diagnosis      
Yes 381 95.49 
Diagnosis       
hEDS 318 79.7 
Previous Diagnosis     
hEDS 73 19.73 
HSD 35 9.46 
Different Type of EDS 19 5.14 
Immune Deficiency or 
Autoimmune Disorder 56 15.14 
Other 186 50.27 
Age of Symptom Onset     
< 10 years old 228 57.14 
10 - 18 years old 116 29.07 
19 - 30 years old 42 10.53 
> 30 years old 13 3.26 
Age at Diagnosis     
< 10 years old 5 1.26 
10 - 18 years old 66 16.58 
19 - 30 years old 161 40.45 
31 - 40 years old 99 24.87 
> 40 years old 67 16.84 
Time Since Diagnosis     
< 1 year 101 25.31 
1 - 2 years 96 24.06 
3 - 5 years 91 22.81 
5 - 10 years 64 16.04 









 Of the participants who completed the survey, greater than 90% indicated they 
experience pain, joint hypermobility, joint dislocations or subluxations, fatigue, gastrointestinal 
issues, skin manifestations, and emotional difficulties [see TABLE 4]. More than 75% of 
participants indicated that they experience cardiovascular issues, neurological issues, and 
sleeping difficulties. Additionally, greater than 50% indicated they experience arthritis, 
Temporomandibular Joint disorder (TMJ), and immunological issues..  
Symptoms and co-morbidities that had the greatest impact (M > 5) on participant’s life 
were pain (M = 6.291, SD = 1.474), joint hypermobility (M = 5.865, SD = 1.5540), joint 
dislocations or subluxations (M = 5.591, SD = 2.115), fatigue (M = 6.211, SD = 1.573), 
gastrointestinal issues (M = 5.546, SD = 2.115), neurological issues (M = 5.441, SD = 2.251), 
emotional difficulties (M = 5.474, SD = 2.123), and sleeping difficulties (M = 5.075, SD = 2.600) 














TABLE 4: Illness Characteristics [N = 399]  
Symptom / Co-morbidity  
IC. Count IC. Impact 
Frequency Percent Mean SD 
Pain (Limb or Joint) 392 98.25 6.291 1.474 
CRPS / RSD 80 23.32 1.083 2.305 
Fibromyalgia 169 45.31 2.516 3.090 
Joint Hypermobility 389 97.49 5.865 1.554 
Joint Dislocations or 
Subluxations 365 91.94 5.591 2.115 
Fatigue 386 97.23 6.211 1.573 
Arthritis 217 57.26 3.060 3.005 
Scoliosis 172 46.74 2.000 2.565 
TMJ 271 71.88 3.521 2.738 
Locked Jaw 143 39.18 1.787 2.547 
Endometriosis 88 24.51 1.261 2.482 
Vulvodynia 53 15.1 0.712 1.918 
Infertility 51 14.7 0.687 1.901 
Gastrointestinal Issues  361 91.62 5.546 2.115 
Cardiovascular Issues 330 85.05 4.932 2.507 
Neurological Issues 353 89.14 5.441 2.251 
Organ Prolapse 76 20.88 1.050 2.253 
Skin Manifestations  362 91.88 4.145 2.075 
Immunological Issues  222 59.2 3.431 3.175 
Emotional Difficulties  362 92.82 5.474 2.123 
Sleeping Difficulties  330 84.18 5.075 2.600 
 
IC. Count: total count of illness characteristics 
IC. Impact: total impact of illness characteristics 
CRPS / RSD: Complex Regional Pain syndrome / Reflex Sympathetic Dystrophy 
TMJ: Temporomandibular Joint disorder 
Gastrointestinal Issues: Irritable Bowel syndrome (IBS), Gastroesophageal Reflux disorder (GERD), gastroparesis, diarrhea, 
constipation, nausea, other functional bowel problems 
Cardiovascular Issues: shortness of breath, tachycardia, palpitations, Postural Orthostatic Tachycardia syndrome (POTS) 
Neurological Issues: headaches/migraines, dizziness, nerve compression, Neurally-mediated Hypotension (NMH), syncope 
Organ Prolapse: uterine, bladder, rectal 
Skin Manifestations: easy bruising, easy scarring, soft / velvety skin 
Immunological Issues: immune deficiency, autoimmune disorder, Mast Cell Activation syndrome (MCAS) 
Emotional Difficulties: anxiety, depression, trouble focusing, brain fog, other mood disorder 





Means of Scales 
Overall, participants viewed hEDS and HSD as threatening (IPQ: M = 62.688, SD = 
8.603). More specifically, participants indicated that their illness has a severe impact on their 
lives (Consequences: M = 9.135, SD = 1.859). Participants perceived hEDS and HSD as lasting 
forever (Timeline: M = 10.570, SD = 1.399). Participants felt they had a moderate amount of 
personal control over their illness (Personal Control: M = 7.463, SD = 2.357) and felt their 
treatment could moderately help their illness (Treatment Control: M = 6.618, SD = 2.522). 
Participants indicated they experienced many severe symptoms (Identity: M = 9.000, SD = 
1.719). This finding is consistent with the count and impact of illness characteristics described in 
the previous section. Participants indicated they are moderately concerned about their hEDS or 
HSD (Concern: M = 8.191, SD = 2.324). Participants felt they had little understanding of their 
illness (Coherence: M = 3.586, SD = 2.347). Participants felt their hEDS or HSD moderately 
affected them emotionally (Emotional Representations: M = 8.105, SD = 2.373).  
When asked to “list in rank-order the three most important factors that you believe caused 
your illness”, the majority of participants indicated “genetics” as the most important causal factor 
that caused hEDS or HSD [see TABLE 5]. Other causal factors ranked first included physical 
stress/injury (4.92%) and psychological stress/trauma (2.73%). Other causal factors ranked 
second included physical stress/injury (21.40%), lack of diagnosis/knowledgeable healthcare 
providers (18.95%), psychological stress/trauma (8.77%), immune dysfunction (6.67%), and 
diet/nutrition/lifestyle (5.26%). Other causal factors ranked third included lack of 
diagnosis/knowledgeable healthcare providers (16.67%), physical stress/injury (15.85%), 
diet/nutrition/lifestyle (6.91%), psychological stress/trauma (6.10%), and immune dysfunction 
(4.47%).   
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TABLE 5: Causal Attributions  
Causal Attribution Frequency Percent 
Causal Factor 1 [n = 366]     
Genetics 319 87.16 
Physical Stress / Injury 18 4.92 
Psychological Stress / Trauma 10 2.73 
Causal Factor 2 [n = 285]     
Genetics 67 23.51 
Physical Stress / Injury 61 21.40 
Lack of Diagnosis / Knowledgeable Healthcare Providers 54 18.95 
Psychological Stress / Trauma 25 8.77 
Immune Dysfunction 19 6.67 
Diet / Nutrition / Lifestyle 15 5.26 
Causal Factor 3 [n = 246]     
Genetics 57 23.17 
Lack of Diagnosis / Knowledgeable Healthcare Providers 41 16.67 
Physical Stress / Injury 39 15.85 
Diet / Nutrition / Lifestyle 17 6.91 
Psychological Stress / Trauma 15 6.10 











Overall, participants perceived moderate uncertainty in their hEDS or HSD (MUIS: M = 
59.080, SD = 10.834). More specifically, participants perceived moderate ambiguity/future 
uncertainty (Ambiguity/Future Uncertainty: M = 36.792, SD = 8.628) and moderate 
unpredictability in their illness (Unpredictability: M = 22.263, SD = 4.730).  
Overall, participants had moderate levels of confidence in their ability to cope (CSE: M = 
6.168, SD = 2.234). More specifically, participants indicated moderate levels of confidence in 
using problem-focused coping (M = 36.792, SD = 8.628), stopping unpleasant thoughts (M = 
5.725, SD = 2.721), and getting support from friends and family (M = 5.971, SD = 2.754).  
Overall, participants had moderate scores on 3 out of the 4 illness identity dimensions 
(Acceptance: M = 2.440, SD = 0.646; Engulfment: M = 2.727, SD = 0.854; Enrichment: M = 
2.279, SD = 0.855). Participants had moderately high scores on the Rejection Identity (M = 
3.579, SD = 0.839). 
Overall, participants had moderate levels of anxiety (M = 61.469, SD = 8.518) and mild 
levels of depression (M = 58.614, SD = 9.148).  
Overall, participants were moderately adapted to living with their hEDS or HSD (PAS: M 
= 2.617, SD = 0.770). More specifically, participants had moderate levels of coping self-efficacy 
(M = 2.592, SD = 0.857). This finding is consistent with the scores on the Coping Self-Efficacy 
scale described previously in this section. They also had moderate levels of self-esteem (M = 
2.511, SD = 0.945), and social integration (M = 2.253, SD = 0.801). Participants indicated they 




Internal Reliability of Scales 
 Most scales showed good internal reliability with α > 0.70. The CSE scale had an α = 
0.9408, the IIQ Rejection state had an α = 0.809, the IIQ Engulfment state had an α = 0.8892, the 
IIQ Enrichment state had an α = 0.9042, the PROMIS Anxiety scale had an α = 0.9273, the 
PROMIS Depression scale had an α = 0.9441, and the PAS had an α = 0.9447. The IPQ scale 
had an α = 0.5712 which indicated poor internal reliability. To increase internal reliability, 
questions 2, 4, and 7 [see APPENDIX 3] were dropped from the total score based on low item-
total correlations which improved internal reliability to an α = 0.717, indicating better internal 
reliability. All further analyses used the modified IPQ scale. The MUIS “Unpredictability” 
subscale had an α = 0.5947 which indicated poor internal reliability. The subscale could not be 
effectively modified and was dropped from all further analyses. The MUIS “Ambiguity/Future 
Uncertainty” subscale had an α = 0.8285, indicating good internal reliability. This subscale was 
used in all further analyses. 
Correlation Analysis 
Relationships with Illness Identities 
 Correlations were examined to assess relationships between predictor variables and each 
of the illness identity states (rejection, acceptance, engulfment, and enrichment) [see TABLE 6]. 
Predictors were diagnosis characteristics, total count of illness characteristics, total impact of 
illness characteristics, total score for illness perceptions, total score for uncertainty, and total 
score for coping self-efficacy. Higher scores in the rejection identity was related to lower number 
of illness characteristics (r = -0.2451, p < 0.001), more perceived impact of illness characteristics 
(r = 0.2773, p < 0.001), more threatening illness perceptions (r = 0.2511, p < 0.001), and more 
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uncertainty (r = 0.1571, p = 0.002). The rejection identity was not related to coping self-efficacy 
(r = 0.0357, p = 0.4768).  Higher scores in the acceptance identity was related to less uncertainty 
(r = -0.1540, p = 0.0031), and less coping self-efficacy (r = -0.1722, p = 0.005). The acceptance 
identity was not related to number of illness characteristics (r = -0.004, p = 0.9433), perceived 
impact of illness characteristics (r = -0.0382, p = 0.4467), or illness perceptions (r = 0.031, p 
=0.5389).  Higher scores in the engulfment identity was related to higher number of illness 
characteristics (r = 0.1501, p = 0.008), less perceived impact of illness characteristics (r = -
0.2329, p < 0.001), less threatening illness perceptions (r = -0.5070, p < 0.001), more uncertainty 
(r = 0.4223, p < 0.001), and more coping self-efficacy (r = 0.4617, p < 0.001).  Higher scores in 
the enrichment identity was related to more threatening illness perceptions (r = 0.1091, p = 
0.0299) and less coping self-efficacy (r = -0.3952, p < 0.001). The enrichment identity was not 
related to number of illness characteristics (r = -0.0204, p = 0.7197), impact of illness 


























Count 1                 
                    
IC. 
Impact -0.8276* 1               
  0                 
IPQ -0.3356* 0.4349* 1             
  0 0               
MUIS 0.0405 -0.0509 -0.2861* 1           
  0.4832 0.3183 0             
CSE 0.1068 -0.088 -0.2940* 0.2712* 1         
  0.0599 0.0792 0 0           
IIQ 
Reject. -0.2451* 0.2773* 0.2511* 0.1571* 0.036 1       
  0 0 0 0.002 0.477         
IIQ 
Accept. -0.004 -0.0382 0.031 -0.1504* -0.1722* -0.4001* 1     
  0.9433 0.4467 0.5389 0.0031 0.0000 0       
IIQ 
Engulf. 0.1501* -0.2329* -0.5070* 0.4223* 0.4617* 0.0259 -0.1161* 1   
  0.008 0 0 0 0 0.6063 0.0203     
IIQ 
Enrich. -0.0204 -0.0322 0.1091* -0.0446 -0.3952* -0.0796 0.2908* -0.1673* 1 
  0.7197 0.521 0.0299 0.3817 0 0.1123 0 0.0008   
 
IC. Count: total count of illness characteristics 
IC. Impact: total impact of illness characteristics 
IPQ: modified Illness Perceptions Questionnaire – brief form 
MUIS: ambiguity/future uncertainty subscale of the Mishel Uncertainty in Illness scale – community form 
CSE: Coping Self-Efficacy Scale 
IIQ Reject: Illness Identity – Rejection dimension 
IIQ Accept: modified Illness Identity – Acceptance dimension  
IIQ Engulf: Illness Identity – Engulfment dimension 







Relationships with Emotional Distress and Psychological Adaptation  
 Correlations were examined to assess relationships between each of the illness identities 
and outcomes [see TABLE 7]. Outcomes were emotional distress (anxiety and depression) and 
psychological adaptation. More anxiety was related to higher acceptance identity (r = 0.1993, p = 
0.002), lower engulfment identity (r = -0.4590, p < 0.001), and higher enrichment identity (r = 
0.1980, p = 0.0001). Anxiety was not related to the rejection identity (r = -0.0637, p = 0.2113). 
More depression was related to higher acceptance identity (r = 1896, p = 0.0001), lower 
engulfment identity (r = -0.6047, p < 0.001), and higher enrichment identity (r = 0.3237, p < 
0.001). Depression was not related to the rejection identity (r = -0.0436, p = 0.3854). More 
psychological adaptation was related to higher acceptance identity (r = 0.2891, p < 0.001), lower 
engulfment identity (r = -0.2051, p < 0.001), higher enrichment identity (r = 0.8078, p < 0.001), 
more anxiety (r = 0.2242, p < 0.001), and more depression (r = 0.3434, p < 0.001). Psychological 



















Enrich. Anxiety Depression PAS 
IIQ  
Reject. 1             
                
IIQ  
Accept. -0.4001* 1           
  0             
IIQ  
Engulf. 0.0259 -0.1161* 1         
  0.6063 0.0203           
IIQ  
Enrich. -0.0796 0.2908* -0.1673* 1       
  0.1123 0 0.0008         
Anxiety -0.0627 0.1883* -0.4590* 0.1980* 1     
  0.2113 0.0002 0 0.0001       
Depression -0.0436 0.1896* -0.6047* 0.3237* 0.7203* 1   
  0.3854 0.0001 0 0 0     
PAS -0.0611 0.2891* -0.2051* 0.8078* 0.2242* 0.3434* 1 
  0.223 0 0 0 0 0   
 
IIQ Reject: Illness Identity – Rejection dimension 
IIQ Accept: modified Illness Identity – Acceptance dimension  
IIQ Engulf: Illness Identity – Engulfment dimension 
IIQ Enrich: Illness Identity – Enrichment dimension 
Anxiety: PROMIS Anxiety t-score 
Depression: PROMIS Depression t-score 











Outcome: Illness Identities  
  Regression models were built to assess predictors of each of the illness identities 
(rejection, acceptance, engulfment, and enrichment). Predictors were diagnosis characteristics, 
total count of illness characteristics, total impact of illness characteristics, total score for illness 
perceptions, total score for uncertainty, and total score for coping self-efficacy. Individuals who 
perceived their illness as threatening (β = 0.0244, t = 2.96, p = 0.003) and uncertain (β = 0.0304, 
t = 4.27, p < 0.001) had higher rejection identity. Individuals with higher coping self-efficacy 
had lower acceptance identity (β = -0.0602, t = -2.75, p = 0.006). Individuals who perceived their 
illness as uncertain had higher engulfment identity (β = 0.0291, t = 5.4, p < 0.001).Individuals 
who perceived their illness as threatening had lower engulfment identity (β = -0.0341, t = -5.45, 
p < 0.001).Individuals with higher coping self-efficacy had higher engulfment identity (β = 
0.1104, t = 5.84, p < 0.001).  Individuals with higher coping self-efficacy had lower enrichment 
identity (β = -0.1627, t = -7.22, p < 0.001).. 
Outcome: Emotional Distress 
Regression models were built to examine the relationships between each illness identity 
state (rejection, acceptance, engulfment, and enrichment) and emotional distress (anxiety and 
depression). Individuals with a higher acceptance identity (β = 1.3346, t = 2.21, p = 0.027) and 
higher enrichment identity (β = 0.9330, t = 2.02, p = 0.045) had higher anxiety. Individuals with 
a higher engulfment identity had less anxiety (β = -4.2888, t = -9.62, p < 0.001).  Individuals 
with a higher enrichment identity (β = 2.2540, t = 5.2, p < 0.001) had more depression and those 
with a higher engulfment identity had less depression (β = -6.0122, t = -14.4, p < 0.001).  
38 
 
Outcome: Psychological Adaptation 
Regression models were built to examine the relationships between each illness identity 
(rejection, acceptance, engulfment, and enrichment) and psychological adaptation. Individuals 
with higher acceptance identity (β = 0.0719, t = 1.98, p = 0.048)  and higher enrichment identity 
(β = 0.7026, t = 25.15, p < 0.001)  had higher psychological adaptation. Individuals with higher 
















Goals of the Study 
This is the first research study to explore many of the concepts used in our study, 
including uncertainty in illness, coping self-efficacy, illness identity, and psychological 
adaptation in the hEDS and HSD populations. One of the goals of our study was to understand if 
and how individuals incorporate their illness into their identity and adapt to living with hEDS or 
HSD. To better understand these processes and outcomes, several concepts were examined in the 
context of the Transactional Model of Stress and Coping (TMSC). These concepts consisted of 
diagnosis and illness characteristics, illness perceptions (as a primary appraisal), uncertainty in 
illness and coping self-efficacy (as secondary appraisals), and emotional distress (anxiety and 
depression) and psychological adaptation (as outcomes). An additional goal of our study was to 
examine how the concept of illness identity may relate or contribute to concepts in the TMSC. 
Illness identity has not previously been examined with many of the concepts used in our study 
including illness perceptions, uncertainty in illness, coping self-efficacy, and psychological 
adaptation. Illness identity has also not previously been examined in the hEDS and HSD 
populations.    
Summary of Results 
Characterization of Study Sample 
Our study included 399 participants. Most participants were female, white, not Hispanic 
or Latino, and had a diagnosis of hEDS. Participants varied on all other demographic variables 
and diagnosis characteristics. Symptoms of pain, joint hypermobility, joint dislocations or 
subluxations, fatigue, gastrointestinal issues, neurological issues, emotional difficulties, and 
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sleeping difficulties were reported by most participants and were perceived as having the greatest 
impact. These demographic, diagnosis, and illness characteristics are consistent with other 
research studies within the hEDS and HSD populations12, 21, 32, 62, 74.    
Overall, participants viewed hEDS and HSD as threatening (M = 62.688, SD = 8.603). 
More specifically, participants viewed their illness as severe, lasting forever, and experienced 
many severe symptoms. There was a general perception of having moderate personal control and 
treatment control over their illness. Participants felt moderately concerned about their illness, 
indicated that they had little understanding of their illness, and felt their illness moderately 
affected them emotionally. These results are consistent with the illness characteristics reported 
previously in our study. Additionally, these results are consistent with a study by Hope and 
colleagues investigating subjective health complaints and illness perceptions among adults with 
hEDS or HSD32.   
Participants perceived moderate uncertainty in their illness and were moderately 
confident in their ability to cope effectively with their illness. Participants had moderate scores 
on 3 out of the 4 illness identity states (Acceptance: M = 2.440, SD = 0.646; Engulfment: M = 
2.727, SD = 0.854; Enrichment: M = 2.279, SD = 0.855). Participants had moderately high scores 
on the Rejection Identity (M = 3.579, SD = 0.839). A study by Oris and colleagues investigating 
illness identity in adults with multisystem connective tissue disorders (specifically systemic 
lupus erythematosus and systemic sclerosis) found similar scores on the illness identity states42. 
Participants had moderate levels of anxiety and mild levels of depression. Many studies have 
reported that a significant minority of individuals with hEDS or HSD have clinically significant 
levels of anxiety and depression9, 22, 23, 75-77. Lastly, participants were moderately adapted to 
living with their hEDS or HSD. 
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Illness Identity as an Outcome 
We hypothesized that individuals with greater number and impact of illness 
characteristics, greater perceptions of their illness as threatening, greater uncertainty in their 
illness, and lower coping self-efficacy would have higher scores in the rejection or engulfment 
identities. As hypothesized, higher scores in rejection were significantly correlated with greater 
perceived impact of illness characteristics, more threatening illness perceptions, and more 
uncertainty. Contrary to hypothesis, higher scores in rejection were significantly correlated with 
lower number of illness characteristics. Also contrary to hypothesis, the rejection identity was 
not correlated with coping self-efficacy. In regression analysis, individuals who felt threatened 
by and uncertain about their illness were significantly more likely to reject hEDS and HSD as 
part of their identity. As hypothesized, higher scores in acceptance were significantly correlated 
with less uncertainty. Contrary to hypothesis, higher scores in acceptance were significantly 
correlated with less coping self-efficacy. Also contrary to hypothesis, the acceptance identity was 
not correlated with number or perceived impact of illness characteristics or illness perceptions.  
In regression analysis, individuals who had higher coping self-efficacy were less likely to accept 
hEDS and HSD as part of their identity. As hypothesized, higher scores in engulfment were 
significantly correlated with higher number of illness characteristics and more uncertainty. 
Contrary to hypothesis, higher scores in engulfment were significantly correlated with less  
perceived impact of illness characteristics, less threatening illness perceptions, and more coping 
self-efficacy. In regression analysis, individuals who viewed their illness as uncertain and had 
higher coping self-efficacy were more likely to become engulfed by hEDS or HSD. Additionally, 
individuals who perceived their illness as threatening were less likely to become engulfed by 
hEDS or HSD. Contrary to hypothesis, higher scores in enrichment were  correlated with more 
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threatening illness perceptions and less coping self-efficacy. Also contrary to hypothesis, the 
engulfment identity was not correlated with number or perceived impact of illness characteristics 
or uncertainty. In regression analysis, individuals with higher coping self-efficacy were less 
likely to be enriched by hEDS or HSD.  
A unique finding in our study was the unexpected relationships among coping self-
efficacy and the illness identity states. We expected that individuals who had more confidence in 
their ability to cope would be more likely to accept their illness as a part of their identity or 
become enriched by it. Our results indicated that individuals who had higher coping self-efficacy 
were more likely to become engulfed by their illness. One possible explanation for this finding 
may be the unique characteristics of the study population. We recruited our participants from the 
EDS Society which is a very active patient advocacy organization. Individuals involved in the 
EDS Society may be more likely to indicate greater confidence in their coping abilities due to the 
available resources and social support. However, the availability of these resources and 
individuals’ confidence in their coping ability may not translate into the processes of coping and 
integrating their illness into their identity. More research is needed to understand the 
relationships among coping self-efficacy and the illness identity states. Additionally, more 
research is needed to understand how individuals with hEDS or HSD coping with their illness 
and integrate it into their identity.  
Relationships Among Illness Identity, Emotional Distress, and Psychological Adaptation 
 We hypothesized that individuals who have higher scores in the rejection or engulfment 
identities would experience more symptoms of anxiety and depression and be less adapted to 
living with their illness. Contrary to hypothesis, the relationships among the illness identity states 
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and symptoms of anxiety and depression were not as expected. The acceptance and enrichment 
identities were significantly correlated with more symptoms of anxiety and depression. The 
engulfment identity was significantly correlated with less symptoms of anxiety and depression. 
The rejection identity was not related to symptoms of anxiety and depression. In regression 
analysis, these findings were recapitulated and individuals with more anxiety were more likely to 
accept hEDS or HSD into their identity or be enriched by it and less likely to be engulfed by it. 
Additionally, individuals with more depression were more likely to be enriched by their hEDS or 
HSD and less likely to become engulfed by it. As hypothesized, the acceptance and enrichment 
identities were significantly correlated with more psychological adaptation. The engulfment 
identity was significantly correlated with less psychological adaptation. Contrary to hypothesis, 
the rejection identity was not related to psychological adaptation. In regression analysis, these 
findings were recapitulated and individuals who were more likely to accept hEDS or HSD into 
their identity or be enriched by it had more psychological adaptation than those who are engulfed 
by their illness. 
A unique finding in our study was the unexpected relationships among the illness identity 
states and symptoms of anxiety and depression. We expected that individuals who were more 
likely to accept their illness as part of their identity or be enriched by it would have less 
symptoms of anxiety and depression. Our results indicated that individuals who were more likely 
to be engulfed by their illness had less symptoms of anxiety and depression. One possible 
explanation for this finding may be that the measures used to capture symptoms of anxiety and 
depression are representative of the state of emotional distress rather than the trait of emotional 
distress. A state of emotional distress is a temporary reaction to a situation in a specific moment 
whereas a trait of emotional distress is a consistent personality attribute. State and trait emotional 
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distress are not always directly correlated. It is possible that the PROMIS measures used in our 
study to capture symptoms of anxiety and depression represents state emotional distress. More 
research is needed to understand the relationships among the illness identity states and emotional 
distress.  
Clinical Implications 
 The results from our research study have implications for clinical care of individuals with 
hEDS or HSD. It is well recognized that hEDS and HSD are chronic conditions and greatly 
affect physical and psychological functioning. Previous research has identified that affected 
individuals experience challenges in managing their condition due to diagnostic uncertainty, lack 
of awareness of hEDS and HSD, lack of access to knowledgeable healthcare providers, limited 
treatment and management options, and potential for disability3, 6, 9, 14, 15, 17, 19, 21-24, 32, 50, 51, 75-79. 
These challenges negatively affect physical functioning and psychological well-being3, 6, 9, 14, 15, 
17, 19, 21-24, 32, 50, 51, 75-79. Understanding how individuals with hEDS or HSD perceive their illness, 
appraise uncertainty and their ability to cope, integrate their illness into their identity, and adapt 
to living with a chronic illness, may allow healthcare providers to intervene in hopes of 
improving health outcomes. For example, Cognitive-Behavior Therapy (CBT) has been shown to 
reduce anxiety, depression, catastrophizing, and improve self-efficacy in individuals with hEDS 
or HSD9, 24. While CBT is widely used in the psychotherapy field, some of its principles may 
also be used by other healthcare providers such as genetic counselors. Genetic counselors can 
utilize CBT principles to affect downstream effects of adaptation such as medical management 
and behavior change49, 80. Genetic counselors may facilitate adaptation by helping affected 
individuals identify coping strategies and resources that fit with their perceptions of their illness. 
Furthermore, this intervention may also lead to changes in behavior such as treatment adherence.  
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As discussed, findings from our research study provide insight into illness identity integration 
and adaptation. Psychotherapeutic interventions have the potential to influence downstream 
clinical outcomes in individuals with hEDS or HSD.  
Limitations 
Although there is extensive research evidence and theories supporting the concepts of 
illness identity and psychological adaptation27, 34, 38, 41, 81, 82, nuances still remain. Studying these 
concepts in different populations and under different circumstances may provide greater 
theoretical understanding and potentially identify more opportunities to affect clinical outcomes. 
The findings from our research study, specifically the unexpected relationships among coping 
self-efficacy, emotional distress, and the illness identity states, need further evaluation. More 
research is needed to determine if the findings from our study are reflective of the hEDS and 
HSD populations or if there are other psychological factors contributing. Despite the important 
clinical and theoretical implications of our research study, there are several limitations. In terms 
of sex, race, ethnicity, and clinical diagnosis our study population was fairly homogenous. 
Although our study population varied on other demographic and diagnostic characteristics, the 
findings may not be generalizable across different groups of individuals with hEDS or HSD. 
Furthermore, recruitment from the EDS Society may contribute to limitations in generalizability 
as well as result in response bias. Individuals not actively involved in the EDS Society may 
differ in key aspects from those who are and those who have participated in our research study. 
As mentioned previously, individuals who are involved in the EDS Society may be more 
motivated to seek resources and social support as a means of coping with their hEDS or HSD. 
Further research is needed to understand the effect of involvement in a patient advocacy 
organization on psychological and health outcomes. Additionally, the self-reported nature of the 
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diagnosis and illness characteristics may contribute to limitations in accurate interpretation or 
translation of our study findings. Lastly, the course of an illness, like hEDS or HSD, changes 
over time. The cross-sectional nature of our study only captures one point in time and may not 
comprehensively evaluate the processes of illness identity integration or adaptation overtime. 
Further research is needed to understand our study’s unique findings and address some of its 
limitations.   
Areas for Future Research 
Our research study is the first to examine relationships among concepts within the 
Transactional Model of Stress and Coping (TMSC) in the hEDS and HSD populations. 
Additionally, this research study is the first to examine the relationships among illness identity 
and concepts within the TMSC. While this research study provides some insight into the 
relationships among concepts in the hEDS and HSD populations, it raises potential nuances in 
and important questions. Further research is needed to better understand how the concepts relate 
to each other and in this specific population. 
Further research is needed to explore how other appraisals, such as uncertainty in 
diagnosis, contribute to adaptive illness identity integration and adaptation in individuals with 
hEDS or HSD. Given the 2017 revision of the hEDS clinical diagnostic criteria2, the creation of 
the diagnostic label of HSD1, 4, and lack of identifiable genetic cause(s) of hEDS and HSD2, 10, 11, 
62, it is reasonable to suspect that some affected individuals may experience uncertainty in their 
diagnosis. Bhise and colleagues define diagnostic uncertainty as a “subjective perception of an 
inability to provide an accurate explanation of the patient’s health problem”83. Accurate 
recognition and diagnosis of hEDS and HSD is an ongoing challenge1-8. Little is known about 
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how healthcare providers communicate diagnostic uncertainty, how patients perceive diagnostic 
uncertainty, and how diagnostic uncertainty affects health outcomes. Furthermore, diagnostic 
uncertainty is not unique to individuals with hEDS or HSD. Many other patients with health 
conditions, suspected genetic or otherwise, may experience diagnostic uncertainty. Despite 
significant advances in medical knowledge and technology, many patients still lack an etiologic 
explanation for their health condition. More research is needed to evaluate the effect of 
diagnostic uncertainty on different health outcomes. In the interim, healthcare providers can help 
patients by facilitating adaptation to living with uncertainty.  
 Other psychological and social factors, such as perceived social stigma, may affect how 
individuals integrate their illness into their identity and adapt to living with hEDS or HSD. The 
chronic pain, fatigue, and comorbidities associated with hEDS and HSD have the potential to 
become disabling for some individuals15, 19, 24, 78. Some individuals feel as though they live a 
“restricted life” due to being limited in their educational pursuits, job opportunities, and social 
activities19. In addition to disability, lack of awareness, understanding, and respect from 
healthcare providers, other professionals, and peers may lead to feelings of stigmatization in 
individuals with hEDS or HSD8, 50, 51. Rybarczyk and colleagues define perceived social stigma 
as a “perception that others hold negative stereotypic attitudes about him or her as a result of a 
disability”84. Individuals with hEDS or HSD may experience stigmatization for a variety of 
reasons8, 15, 19, 24, 50, 51, 78. Based on previous work on illness, identity, and self in other 
populations29, it is reasonable to suspect that perceived social stigma may influence illness 
identity integration and adaptation in individuals with hEDS or HSD. More research is needed to 
understand if and how individuals with hEDS or HSD experience stigma and its relation to 
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different health outcomes. In the meantime, healthcare providers can listen to patients’ narratives 




















 Our study is one of the only studies to assess psychological processes and outcomes in 
the hEDS and HSD populations. Exploration of relationships between diagnosis and illness 
characteristics, illness perceptions, illness uncertainty, and coping self-efficacy with illness 
identity revealed unique findings. Unexpectedly, higher coping self-efficacy was related the 
rejection and engulfment illness identities whereas lower coping self-efficacy was related to 
acceptance and enrichment illness identities. Additionally, exploration of relationships between 
illness identity, emotional distress, and psychological adaptation revealed unique findings. 
Unexpectedly, more symptoms of anxiety and depression were related to acceptance and 
enrichment identities whereas less symptoms of anxiety and depression were related to rejection 
and engulfment identities. More research is needed to understand these unique findings. Our 
study contributes to better understanding of the illness experiences of individuals with hEDS or 
HSD and provides a possible opportunity for genetic counselors to facilitate illness integration 













Dear Potential Research Participant, 
You are invited to participate in a study conducted by researchers at the Johns Hopkins 
Bloomberg School of Public Health and the National Human Genome Research Institute. The 
purpose of this study is to learn more about the experiences of individuals living with 
Hypermobile Ehlers Danlos Syndrome (hEDS) or Hypermobility Spectrum Disorder (HSD). The 
information you provide may help to improve our understanding of the patient’s perspective with 
regards to having a diagnosis and the impact of these conditions. 
The study involves filling out a survey, which we anticipate will take about 30-40 minutes to 
complete. The survey asks questions about your diagnosis, symptoms, and thoughts and feelings 
about living with your condition. Individuals who join in this study will receive a $5.00 gift card 
as a token of our appreciation for their time. 
You may participate in the study if: 
1. You are 18 years or older 
2. You can read and write English 
3. You have a diagnosis of hEDS or HSD 
The survey can be found online at _________________________________________________. 
If you are willing to take part in the study, please read the study information form on the first 
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William Klein, PhD 
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STUDY INFORMATION FORM 
You are invited to participate in a study conducted by researchers at the Johns Hopkins 
Bloomberg School of Public Health and the National Human Genome Research Institute. 
Why is this study being done? To learn more about the lived experiences of individuals with 
Hypermobile Ehlers Danlos Syndrome (hEDS) or Hypermobility Spectrum Disorder (HSD). 
Who can participate in the study? We are interested in hearing from individuals who have 
been told by a healthcare provider that they have hEDS or HSD. You must be 18 years of age or 
older and able to read and write in English. 
What is involved in the study? There is one survey that takes approximately 30-40 minutes to 
complete. The survey asks questions about your diagnosis, symptoms, and thoughts and feelings 
about living with your condition. 
What are the risks to the study? There are no known risks of taking part in the study. If taking 
the survey causes any discomfort, you can stop taking the survey at any time. If you have 
questions or concerns regarding your diagnosis or have other medical health concerns, please 
contact your specialist who manages your condition or your primary care provider. If you are 
looking for more information regarding hEDS or HSD, please contact the EDS HelpLine at (866-
616-1735). If you feel upset or anxious after taking the survey, please contact the EDS HelpLine 
at (866-616-1735) or free crisis support services at (800-273-8255). If you feel upset or anxious 
after taking the survey you can contact the researcher using the information provided below. 
Are there benefits to taking part in the study? You will not personally receive any benefits 
from taking part in this study. However, we hope to learn more about the lived experiences of 
individuals with these conditions and that this knowledge will advance science and improve 
genetic services. 
Do I have to participate? You do not have to participate in this study. You can skip any 
question or stop taking the survey at any time. Choosing not to participate will not affect your 
participation in any other research study or your healthcare. 
Will I be paid for being part of this research study? You will be offered the opportunity to 
receive a $5.00 gift card after completing the survey. You will be asked at the end of the survey 
to provide your email address to receive the gift card electronically. Any contact information you 
give to the researchers will be destroyed after the gift card is sent and will not be linked in any 





Who else will know that I am in the study? You will not be required to give your name or 
contact information to participate in the study if you prefer not to. If you provide us with your 
name and/or contact information by contacting the researchers directly or accepting the gift card, 
we will not link your name, email, and/or other contact information with your responses. We will 
not share your contact information with anyone outside the research team or use it for any other 
purpose than giving you the survey and/or the gift card. Your responses to the survey will not be 
part of any medical record. When we report our research results, it will be done without reporting 
any identifiable information from individual participants. 
How do I participate? The survey can be completed by advancing to the next screen. 
Will I be told about the study findings? After the study is complete, we plan on posting the 
summary of findings to the EDS Society website. 
 
Please check the box below if you have read and understand the information presented in this 
study information form 
□ I understand the purpose and procedures of the study. 
 
If you are interested in participating in other research studies or being involved in the EDS 
Society’s Global Registry please follow the links below.  
https://www.ehlers-danlos.com/research/   
https://www.ehlers-danlos.com/eds-global-registry/  
 
Thank you for your interest and time! Please contact the researchers (contact information below) 
with any questions or concerns. 
 
Researchers Contact Information: 
Alexis Heidlebaugh 
Student Investigator 
Johns Hopkins Bloomberg School of Public Health 






William Klein, PhD 
Associate Investigator 
National Cancer Institute 
National Human Genome Research Institute 
kleinwm@mail.nih.gov  
 
Lori Erby, PhD, ScM 
Associate Investigator 























Section 1: Eligibility Screen 
Instructions: Please answer the following questions to determine your eligibility to participate in 
this study. 
1. Have you been told by a healthcare provider that you have hEDS or HSD? 
□ Yes 
□ No 
























Section 2: Demographic Information 
Instructions: Please indicate which categories you identify with. 











3. Race (Check all that apply) 
□ American Indian/Native Alaskan 
□ Asian 
□ Black/African American 




□ Hispanic or Latino 
□ Not Hispanic or Latino 
5. Marital Status 
□ Single/Never Married 




6. Highest Level of Education 
□ Elementary/Junior High 
□ High School/GED 
□ Technical School 
□ Some College 









Section 3: Diagnosis Characteristics 
Instructions: These questions ask about your experience with receiving a diagnosis of hEDS or 
HSD. Please select one answer for each of the following questions below. 





2. For the healthcare provider who diagnosed your condition, which condition did he or she 
diagnose you with? 
□ hEDS 
□ HSD 
□ Other (please explain) 
3. What other diagnoses have you been given in the past? 
□ hEDS 
□ HSD 
□ Marfan Syndrome/Loeys-Dietz Syndrome 
□ Different Type of EDS 
□ Immune Deficiency or Autoimmune Disorder  
□ Other (please explain) 
4. At what age did you first notice signs or symptoms of hEDS or HSD? 
□ <10  
□ 10-18  
□ 19-30 
□ 31-40 
□ 41-50  
□ 51-60 
□ >60 
5. At what age were you diagnosed with hEDS or HSD?  
□ <10  
□ 10-18  
□ 19-30 
□ 31-40 
□ 41-50  
□ 51-60 
□ >60 
6. How much time has passed since your diagnosis of hEDS or HSD?  
□ <1 Year 
□ 1-2 Years 
□ 3-5 Years 
□ 5-10 Years 





Section 4: Illness Characteristics  
Instructions: These questions ask about the symptoms of your hEDS or HSD. Please select one 
answer for each of the following questions below. 
  I have 
experienced 
this symptom 
(Only if yes is selected for previous response) 
This symptom has a significant impact on my life. 











1 Pain (limb or joint)        
2 CRPS/RSD        
3 Fibromyalgia        
4 Joint Hypermobility        
5 Joint Dislocations or 
Subluxations 
       
6 Fatigue         
7 Arthritis        
8 Scoliosis        
9 TMJ        
10 Locked Jaw        
11 Endometriosis        
12 Vulvodynia        
13 Infertility        
14 Gastrointestinal Issues (one 
or more of the following: 
IBS, GERD, gastroparesis, 
diarrhea, constipation, 
nausea, other functional 
bowel problems) 
       
15 Cardiovascular Issues (one 
of more of the following: 
shortness of breath, 
tachycardia, palpitations, 
POTS) 
       
16 Neurological Issues (one or 





       
17 Organ Prolapse (one of 
more if the following: 
uterine, bladder, rectal) 
       
18 Skin Manifestations (one or 
more of the following: easy 
bruising, easy scarring, 
soft/velvety skin) 
       
19 Immunological Issues (one 




       
20 Emotional Difficulties (one 
of more of the following: 
anxiety, depression, trouble 
focusing, brain fog, other 
mood disorder) 
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21 Sleeping Difficulties (one 
of more of the following: 
insomnia, RLS) 



























Section 5: Brief Illness Perceptions Questionnaire (IPQ-B) 
Instructions: Please indicate which response best corresponds to your views of hEDS or HSD.  












































1 How much does your 
illness affect your life? 
           

































2 How long do you think 
your illness  will 
continue? 
           












































3 How much control do 
you feel you have over 
your illness? 
           

































4 How much do you think 
your treatment can help 
your illness? 
           












































5 How much do you 
experience symptoms 
from your illness? 
           

































6 How concerned are you 
about your illness? 












































7 How well do you feel 
you understand your 
illness? 
           












































8 How much does your 
illness affect you 
emotionally (does it 
make you feel angry, 
scared, upset, 
depressed)? 
           
Causes            
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9 Please list in rank-order 
the three most 
important factors that 
you believe caused your 
illness. 


























Section 6: Mishel Uncertainty in Illness-Community Form (MUIS-C) 
Instruction. Please indicate how uncertain you are about the following aspects of hEDS or HSD. 
  Strongly 
Disagree  
Disagree  Neither 
Agree nor 
Disagree 
Agree  Strongly 
Agree  
Ambiguity/Future Uncertainty      
1 I don’t know what is wrong with me      
2 I have a lot of questions without answers      
3 I am unsure if my illness is getting worse of 
better 
     
4 The explanations they give seem hazy to me      
5 My symptoms continue to change 
unpredictably 
     
6 The doctors say things to me that could have 
many meanings 
     
7 My treatment is too complex to figure out      
8 It is difficult to know if the treatments of 
medication I am getting are helping me 
     
9 Because of the unpredictability of my illness, I 
cannot plan for the future 
     
10 The course of my illness keeps changing, I 
have my good and bad days 
     
11 It is not clear what is going to happen to me      
12 The effectiveness of the treatment is 
undetermined  
     
13 Because of the treatment, what I can do and 
cannot do keeps changing 
     
14 They have not given me a specific diagnosis      
Unpredictability       
1 I can predict how long my illness will last      
2 I usually know if I am going to have a good or 
bad day 
     
3 I can generally predict the course of my illness      
4 My physical distress is predictable, I know 
when it is going to get better or worse  
     
5 My diagnosis is definite and will not change      
6 The seriousness of my illness has been 
determined 
     
7 I’m certain that they will not find anything else 
wrong with me 
     
8 The doctors and nurses use everyday language 
so I can understand what they are saying 










Section 7: Coping Self-Efficacy Scale (CSE) 
Instructions: When things are not going well for you, or when you’re having problems, how 
confident or certain are you that you can do the following: 














































           
1 Break an upsetting 
problem down into 
smaller parts 
           
2 Sort out what can be 
changed, and what 
cannot be changed 
           
3 Make a plan of action 
and follow it when 
confronted with a 
problem 
           
4 Leave options open 
when things get 
stressful 
           
5 Think about one part 
of the problem at a 
time 
           
6 Find solutions to your 
most difficult 
problems 
           
Stop unpleasant emotions 
and thoughts 
           
1 Make unpleasant 
thoughts go away 
           
2 Take your mind off 
unpleasant thoughts 
           
3 Stop yourself from 
being upset by 
unpleasant thoughts 
           
4 Keep from feeling sad            
Get support from friends 
and family 
           
1 Get friends to help 
you with the things 
you need 
           
2 Get emotional support 
from friends and 
family  
           







Section 8: Illness Identity Questionnaire (IIQ) 
Instructions: We want to know how hEDS or HSD is a part of you. Please indicate how much 
you agree or disagree with the following statements. 
  Strongly 
Disagree  
Disagree  Neither 
Agree or 
Disagree 
Agree  Strongly 
Agree 
Rejection      
1 I refuse to see my illness as part of myself      
2 I’d rather not think of my illness      
3 I hate being talked to about my illness      
4 I never talk to others about my illness      
5 I just avoid thinking about my illness      
Acceptance      
1 My illness simply belongs to me as a person      
2 My illness is part of who I am       
3 I accept being a person with illness      
4 I am able to place my illness in my life      
5 I have learned to accept the limitations imposed 
by my illness 
     
Engulfment      
1 My illness dominates my life      
2 My illness has a strong impact on how I see 
myself 
     
3 I am preoccupied with my illness      
4 My illness influences all my thoughts and 
feelings 
     
5 My illness completely consumes me      
6 It seems as if everything I do, is influenced by 
my illness 
     
7 My illness prevents me from doing what I 
would really like to do 
     
8 My illness limits me in many things that are 
important to me 
     
Enrichment      
1 Because of my illness, I have grown as a person      
2 Because of my illness, I know what I want out 
of life 
     
3 Because of my illness, I have become a stronger 
person 
     
4 Because of my illness, I realize what is really 
important in life 
     
5 Because of my illness, I have learned a lot about 
myself 
     
6 Because of my illness, I have learned to work 
through problems and not just give up 
     
7 Because of my illness, I have learned to enjoy 
the moment more 







Section 9: PROMIS Emotional Distress 
Instructions: Please indicate how often you have felt the following statements in the past 7 days.  
 Never Rarely  Sometimes Often Always 
Anxiety-Short Form 8a      
1 I felt fearful      
2 I found it hard to focus on anything other than 
my anxiety 
     
3 My worries overwhelmed me      
4 I felt uneasy      
5 I felt nervous      
6 I felt like I needed help for my anxiety      
7 I felt anxious      
8 I felt tense      
Depression-Short Form 8a      
1 I felt worthless      
2 I felt helpless      
3 I felt depressed      
4 I felt hopeless      
5 I felt like a failure      
6 I felt unhappy      
7 I felt that I had nothing to look forward to      


















Section 10: Psychological Adaptation Scale (PAS) 
Instructions: Please indicate how much you agree or disagree with the following statements. 
Living with hEDS or HSD has… 







Coping Efficacy      
1 Helped me accept the way things work out      
2 Helped me learn to deal better with 
uncertainty  
     
3 Taught me how to adjust to things I cannot 
change 
     
4 Helped me take things as they come      
5 Helped me to look at things in a more 
positive way 
     
Self-Esteem      
1 Helped me learn to handle difficult times      
2 Helped me become more comfortable with 
who I am 
     
3 Helped me become a stronger person      
4 Helped me feel better about my ability to 
handle problems 
     
5 Helped me to become a better person      
Social Integration      
1 Helped me know who I can count on in 
times of trouble 
     
2 Makes me more willing to help others      
3 Helped relationships become more 
meaningful 
     
4 Helped me become closer to people I care 
about 
     
5 Helped me become more aware of the love 
and support available from other people 
     
Spiritual Well-Being      
1 Helped me learn my life is more meaningful      
2 Given me a greater appreciation for life      
3 Helped me develop a deeper sense of 
purpose in life 
     
4 Helped me feel peaceful      
5 Helped me find strengths in my faith or 
spiritual beliefs 










1 Castori M, Tinkle B, Levy H, Grahame R, Malfait F, Hakim A. A framework for the 
classification of joint hypermobility and related conditions. American Journal of Medical 
Genetics Part C: Seminars in Medical Genetics. 2017;175(1):148-57. 
2 Malfait F, Francomano C, Byers P, et al. The 2017 international classification of the Ehlers–
Danlos syndromes. American Journal of Medical Genetics Part C: Seminars in Medical Genetics. 
2017;175(1):8-26. 
3 Gazit Y, Jacob G, Grahame R. Ehlers–Danlos Syndrome—Hypermobility Type: A Much 
Neglected Multisystemic Disorder. Rambam Maimonides Medical Journal. 2016 
10/31;7(4):e0034. 
4 Forghani I. Hypermobile Ehlers Danlos Syndrome. Balkan medical journal. 2018 Jul 31. 
5 Colombi M, Dordoni C, Chiarelli N, Ritelli M. Differential diagnosis and diagnostic flow chart 
of joint hypermobility syndrome/ehlers-danlos syndrome hypermobility type compared to other 
heritable connective tissue disorders. American Journal of Medical Genetics Part C: Seminars in 
Medical Genetics. 2015;169(1):6-22. 
6 Challal S, Minichiello E, Funalot B, Boissier M-C. Ehlers–Danlos syndrome in rheumatology: 
Diagnostic and therapeutic challenges. Joint Bone Spine. 2015 2015/10/01/;82(5):305-7. 
7 Tinkle B, Castori M, Berglund B, et al. Hypermobile Ehlers–Danlos syndrome (a.k.a. Ehlers–
Danlos syndrome Type III and Ehlers–Danlos syndrome hypermobility type): Clinical 
description and natural history. American Journal of Medical Genetics Part C: Seminars in 
Medical Genetics. 2017;175(1):48-69. 
8 Castori M, Morlino S, Celletti C, et al. Re-writing the natural history of pain and related 
symptoms in the joint hypermobility syndrome/Ehlers–Danlos syndrome, hypermobility type. 
American Journal of Medical Genetics Part A. 2013;161(12):2989-3004. 
9 Baeza-Velasco C, Bulbena A, Polanco-Carrasco R, Jaussaud R. Cognitive, emotional, and 
behavioral considerations for chronic pain management in the Ehlers–Danlos syndrome 
hypermobility-type: a narrative review. Disability and Rehabilitation. 2018:1-9. 
10 Tinkle BT, Bird HA, Grahame R, Lavallee M, Levy HP, Sillence D. The lack of clinical 
distinction between the hypermobility type of Ehlers–Danlos syndrome and the joint 
hypermobility syndrome (a.k.a. hypermobility syndrome). American Journal of Medical 
Genetics Part A. 2009 2009/11/01;149A(11):2368-70. 
11 Levy HP. Hypermobile Ehlers-Danlos Syndrome. In: Adam MP, Ardinger HH, Pagon RA, et 
al., editors. GeneReviews((R)). Seattle (WA): University of Washington, Seattle; 1993. 
12 Castori M, Camerota F, Celletti C, et al. Natural history and manifestations of the 
hypermobility type Ehlers-Danlos syndrome: a pilot study on 21 patients. American journal of 
medical genetics Part A. 2010 Mar;152a(3):556-64. 
13 Hakim A, De Wandele I, O'Callaghan C, Pocinki A, Rowe P. Chronic fatigue in Ehlers–
Danlos syndrome—Hypermobile type. American Journal of Medical Genetics Part C: Seminars 
in Medical Genetics. 2017;175(1):175-80. 
14 Johannessen EC, Reiten HS, Løvaas H, Maeland S, Juul-Kristensen B. Shoulder function, 
pain and health related quality of life in adults with joint hypermobility syndrome/Ehlers–Danlos 
syndrome-hypermobility type. Disability and Rehabilitation. 2016 2016/07/02;38(14):1382-90. 
15 Scheper MC, de Vries JE, Verbunt J, Engelbert RHH. Chronic pain in hypermobility 
syndrome and Ehlers–Danlos syndrome (hypermobility type): it is a challenge. Journal of Pain 
Research. 2015 08/20;8:591-601. 
68 
 
16 Syx D, De Wandele I, Rombaut L, Malfait F. Hypermobility, the Ehlers-Danlos syndromes 
and chronic pain. Clinical and experimental rheumatology. 2017 Sep-Oct;35 Suppl 107(5):116-
22. 
17 Voermans NC, Knoop H, Bleijenberg G, van Engelen BG. Pain in ehlers-danlos syndrome is 
common, severe, and associated with functional impairment. Journal of pain and symptom 
management. 2010 Sep;40(3):370-8. 
18 Rombaut L, Malfait F, Cools A, De Paepe A, Calders P. Musculoskeletal complaints, physical 
activity and health-related quality of life among patients with the Ehlers-Danlos syndrome 
hypermobility type. Disabil Rehabil. 2010;32(16):1339-45. 
19 Berglund B, Nordstrom G, Lutzen K. Living a restricted life with Ehlers-Danlos syndrome 
(EDS). Int J Nurs Stud. 2000 Apr;37(2):111-8. 
20 Muriello M, Clemens JL, Mu W, et al. Pain and sleep quality in children with non-vascular 
Ehlers-Danlos syndromes. American journal of medical genetics Part A. 2018 Sep;176(9):1858-
64. 
21 Murray B, Yashar BM, Uhlmann WR, Clauw DJ, Petty EM. Ehlers-Danlos syndrome, 
hypermobility type: A characterization of the patients' lived experience. American journal of 
medical genetics Part A. 2013 Dec;161a(12):2981-8. 
22 Baeza-Velasco C, Bourdon C, Montalescot L, et al. Low- and high-anxious hypermobile 
Ehlers–Danlos syndrome patients: comparison of psychosocial and health variables. 
Rheumatology International. 2018 May 01;38(5):871-8. 
23 Hershenfeld SA, Wasim S, McNiven V, et al. Psychiatric disorders in Ehlers–Danlos 
syndrome are frequent, diverse and strongly associated with pain. Rheumatology International. 
2016 March 01;36(3):341-8. 
24 Scheper MC, Juul-Kristensen B, Rombaut L, Rameckers EA, Verbunt J, Engelbert RH. 
Disability in Adolescents and Adults Diagnosed With Hypermobility-Related Disorders: A 
Meta-Analysis. Archives of Physical Medicine and Rehabilitation. 2016 
2016/12/01/;97(12):2174-87. 
25 Lazarus RS, Folkman S. Stress, appraisal, and coping.  1984  [cited; Available from: 
http://www.dawsonera.com/depp/reader/protected/external/AbstractView/S9780826141927 
26 Folkman S, Lazarus RS, Gruen RJ, DeLongis A. Appraisal, coping, health status, and 
psychological symptoms. Journal of personality and social psychology. 1986;50(3):571. 
27 Leventhal H, Nerenz, D.R., Steele, D.J. Illness representations and coping with health threats. 
In: Baum A TS, Singer JE. , editor. Handbook of Psychology and Health: Social Psychological 
Aspects of Health. Hillsdale, NJ: Earlbaum; 1984. p. 219-52. 
28 Leventhal H, Leventhal EA, Contrada RJ. Self-regulation, health, and behavior: A perceptual-
cognitive approach. Psychology & health. 1998 1998/07/01;13(4):717-33. 
29 Charmaz K. The Body, Identity, and Self: Adapting to Impairment. The Sociological 
Quarterly. 1995;36(4):657-80. 
30 Weinman J, Petrie KJ, Moss-morris R, Horne R. The illness perception questionnaire: A new 
method for assessing the cognitive representation of illness. Psychology & health. 1996 
1996/03/01;11(3):431-45. 
31 Broadbent E, Petrie KJ, Main J, Weinman J. The Brief Illness Perception Questionnaire. 
Journal of psychosomatic research. 2006;60(6):631-7. 
32 Hope L, Juul-Kristensen B, Løvaas H, Løvvik C, Maeland S. Subjective health complaints 
and illness perception amongst adults with Joint Hypermobility Syndrome/Ehlers–Danlos 
Syndrome-HypermobilityType – a cross-sectional study. Disability and Rehabilitation. 2017:1-8. 
69 
 
33 Han PKJ, Klein WMP, Arora NK. Varieties of Uncertainty in Health Care:A Conceptual 
Taxonomy. Medical Decision Making. 2011;31(6):828-38. 
34 Mishel MH. Uncertainty in Illness. Image: the Journal of Nursing Scholarship. 
1988;20(4):225-32. 
35 Mishel MH. Uncertainty in chronic illness. Annual review of nursing research. 1999;17:269-
94. 
36 Mishel MH. The measurement of uncertainty in illness. Nursing research. 1981 Sep-
Oct;30(5):258-63. 
37 Han PK, Umstead KL, Bernhardt BA, et al. A taxonomy of medical uncertainties in clinical 
genome sequencing. Genet Med. 2017 Jan 19. 
38 Chesney MA, Neilands TB, Chambers DB, Taylor JM, Folkman S. A validity and reliability 
study of the coping self-efficacy scale. British journal of health psychology. 2006;11(Pt 3):421-
37. 
39 Erikson EH. Identity : youth and crisis; 1968. 
40 Oris L, Rassart J, Prikken S, et al. Illness Identity in Adolescents and Emerging Adults With 
Type 1 Diabetes: Introducing the Illness Identity Questionnaire. Diabetes Care. 2016;39(5):757-
63. 
41 Van Bulck L, Luyckx K, Goossens E, Oris L, Moons P. Illness identity: Capturing the 
influence of illness on the person’s sense of self. European Journal of Cardiovascular Nursing. 
2019;18(1):4-6. 
42 Oris L, Luyckx K, Rassart J, et al. Illness Identity in Adults with a Chronic Illness. Journal of 
clinical psychology in medical settings. 2018 Feb 21. 
43 Luyckx K, Oris L, Raymaekers K, et al. Illness identity in young adults with refractory 
epilepsy. Epilepsy & Behavior. 2018 2018/03/01/;80:48-55. 
44 Van Bulck L, Goossens E, Luyckx K, Oris L, Apers S, Moons P. Illness Identity: A Novel 
Predictor for Healthcare Use in Adults With Congenital Heart Disease. Journal of the American 
Heart Association. 2018 May 22;7(11). 
45 Luyckx K, Oris L, Raymaekers K, et al. Illness identity in young adults with refractory 
epilepsy. Epilepsy & behavior : E&B. 2018 Mar;80:48-55. 
46 Taylor SE. Adjustment to threatening events: A theory of cognitive adaptation. American 
Psychologist. 1983;38(11):1161-73. 
47 Taylor SE, Brown JD. Illusion and well-being: A social psychological perspective on mental 
health. Psychological bulletin. 1988;103(2):193-210. 
48 Biesecker BB, Erby LH, Woolford S, et al. Development and validation of the Psychological 
Adaptation Scale (PAS): use in six studies of adaptation to a health condition or risk. Patient 
Education and Counseling,. 2013 Nov;93(2):248-54. 
49 Biesecker BB, Erby L. Adaptation to living with a genetic condition or risk: a mini-review. 
Clinical Genetics,. 2008 Nov;74(5):401-7. 
50 Berglund B, Anne-Cathrine M, Randers I. Dignity not fully upheld when seeking health care: 
experiences expressed by individuals suffering from Ehlers-Danlos syndrome. Disabil Rehabil. 
2010;32(1):1-7. 
51 Terry RH, Palmer ST, Rimes KA, Clark CJ, Simmonds JV, Horwood JP. Living with joint 
hypermobility syndrome: patient experiences of diagnosis, referral and self-care. Family 
Practice. 2015 04/24;32(3):354-8. 
70 
 
52 Chopra P, Tinkle B, Hamonet C, et al. Pain management in the Ehlers–Danlos syndromes. 
American Journal of Medical Genetics Part C: Seminars in Medical Genetics. 2017;175(1):212-
9. 
53 Bovet C, Carlson M, Taylor M. Quality of life, unmet needs, and iatrogenic injuries in 
rehabilitation of patients with Ehlers–Danlos Syndrome hypermobility type/Joint Hypermobility 
Syndrome. American Journal of Medical Genetics Part A. 2016;170(8):2044-51. 
54 Turriff A, Levy HP, Biesecker B. Factors associated with adaptation to Klinefelter syndrome: 
the experience of adolescents and adults. Patient Education and Counseling,. 2015 Jan;98(1):90-
5. 
55 Yanes T, Humphreys L, McInerney-Leo A, Biesecker BJJoGC. Factors Associated with 
Parental Adaptation to Children with an Undiagnosed Medical Condition. 2017 August 
01;26(4):829-40. 
56 Truitt M, Biesecker B, Capone G, Bailey T, Erby L. The role of hope in adaptation to 
uncertainty: the experience of caregivers of children with Down syndrome. Patient Education 
and Counseling,. 2012 May;87(2):233-8. 
57 Lamb AE, Biesecker BB, Umstead KL, Muratori M, Biesecker LG, Erby LH. Family 
functioning mediates adaptation in caregivers of individuals with Rett syndrome. Patient Educ 
Couns. 2016 Nov;99(11):1873-9. 
58 Peay HL, Meiser B, Kinnett K, Furlong P, Porter K, Tibben A. Mothers' psychological 
adaptation to Duchenne/Becker muscular dystrophy. European journal of human genetics : 
EJHG. 2016 May;24(5):633-7. 
59 Peay HL, Rosenstein DL, Biesecker BB. Adaptation to bipolar disorder and perceived risk to 
children: a survey of parents with bipolar disorder. BMC Psychiatry. 2013 2013/12/02;13(1):327. 
60 Shapira R, Turbitt E, Erby LH, Biesecker BB, Klein WMP, Hooker GWJFC. Adaptation of 
couples living with a high risk of breast/ovarian cancer and the association with risk-reducing 
surgery. 2018 October 01;17(4):485-93. 
61 Cohen J. Statistical power analysis for the behavioral sciences. Hillsdale, N.J.: L. Erlbaum 
Associates; 1988. 
62 De Wandele I, Rombaut L, Malfait F, De Backer T, De Paepe A, Calders P. Clinical 
heterogeneity in patients with the hypermobility type of Ehlers-Danlos Syndrome. Research in 
Developmental Disabilities. 2013 2013/03/01/;34(3):873-81. 
63 Løchting I, Garratt A, Storheim K, Werner E, Grotle MJJPR. Evaluation of the brief illness 
perception questionnaire in sub-acute and chronic low back pain patients: data quality, reliability 
and validity. 2013;2(122):2167-0846.1000122. 
64 Tiemensma J, Gaab E, Voorhaar M, Asijee G, Kaptein AAJIjocopd. Illness perceptions and 
coping determine quality of life in COPD patients. 2016;11:2001. 
65 Broadbent E, Wilkes C, Koschwanez H, Weinman J, Norton S, Petrie KJ. A systematic 
review and meta-analysis of the Brief Illness Perception Questionnaire. Psychology & health. 
2015;30(11):1361-85. 
66 Wright LJ, Afari N, Zautra A. The illness uncertainty concept: A review. Current Pain and 
Headache Reports. 2009 2009/03/14;13(2):133. 
67 Nicholls AR, Polman R, Levy AR. Coping self-efficacy, pre-competitive anxiety, and 




68 Cella D, Choi SW, Condon DM, et al. PROMIS((R)) Adult Health Profiles: Efficient Short-
Form Measures of Seven Health Domains. Value in health : the journal of the International 
Society for Pharmacoeconomics and Outcomes Research. 2019 May;22(5):537-44. 
69 Ader DN. Developing the Patient-Reported Outcomes Measurement Information System 
(PROMIS). 2007;45(5):S1-S2. 
70 Pilkonis PA, Choi SW, Reise SP, Stover AM, Riley WT, Cella D. Item Banks for Measuring 
Emotional Distress From the Patient-Reported Outcomes Measurement Information System 
(PROMIS®): Depression, Anxiety, and Anger. 2011;18(3):263-83. 
71 Turriff A, Levy HP, Biesecker B. Factors associated with adaptation to Klinefelter syndrome: 
the experience of adolescents and adults. Patient education and counseling. 2015;98(1):90-5. 
72 StataCorp. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC; 2017. 
73 Cronbach LJJp. Coefficient alpha and the internal structure of tests. 1951;16(3):297-334. 
74 Fontana A, Copetti M, Grammatico P, Morlino S, Colombi M, Castori M. Severity classes in 
adults with hypermobile Ehlers–Danlos syndrome/hypermobility spectrum disorders: a pilot 
study of 105 Italian patients. 2019. 
75 Bulbena A, Baeza-Velasco C, Bulbena-Cabré A, et al. Psychiatric and psychological aspects 
in the Ehlers–Danlos syndromes. American Journal of Medical Genetics Part C: Seminars in 
Medical Genetics. 2017;175(1):237-45. 
76 Berglund B, Pettersson C, Pigg M, Kristiansson P. Self-reported quality of life, anxiety and 
depression in individuals with Ehlers-Danlos syndrome (EDS): a questionnaire study. BMC 
Musculoskeletal Disorders. 2015;16:89. 
77 Sinibaldi L, Ursini G, Castori M. Psychopathological manifestations of joint hypermobility 
and joint hypermobility syndrome/ Ehlers-Danlos syndrome, hypermobility type: The link 
between connective tissue and psychological distress revised. American journal of medical 
genetics Part C, Seminars in medical genetics. 2015 Mar;169c(1):97-106. 
78 Berglund B, Mattiasson AC, Nordstrom G. Acceptance of disability and sense of coherence in 
individuals with Ehlers-Danlos syndrome. Journal of clinical nursing. 2003 Sep;12(5):770-7. 
79 Voermans NC, Knoop H. Both pain and fatigue are important possible determinants of 
disability in patients with the Ehlers-Danlos syndrome hypermobility type. Disabil Rehabil. 
2011;33(8):706-7. 
80 Haakonsen Smith C, Turbitt E, Muschelli J, et al. Feasibility of Coping Effectiveness 
Training for Caregivers of Children with Autism Spectrum Disorder: a Genetic Counseling 
Intervention. J Genet Counsel. 2018;27(1):252-62. 
81 Lazarus RS, Folkman S. Stress, appraisal, and coping. New York: Springer Pub. Co.; 1984. 
82 Hall SS, Burns DD, Reiss AL. Modeling family dynamics in children with fragile x 
syndrome. Journal of abnormal child psychology. 2007 Feb;35(1):29-42. 
83 Bhise V, Rajan SS, Sittig DF, Morgan RO, Chaudhary P, Singh H. Defining and Measuring 
Diagnostic Uncertainty in Medicine: A Systematic Review. Journal of General Internal 
Medicine. 2018;33(1):103-15. 
84 Rybarczyk B, Nyenhuis DL, Nicholas JJ, Cash SM, Kaiser J. Body image, perceived social 







ALEXIS R. HEIDLEBAUGH 
80 Mount Zion Road York, PA 17402 
717.855.8260 




Johns Hopkins University / National Institutes of Health 
Baltimore, MD / Bethesda, MD      Aug 2017-Jan 2020 
Master of Science in Genetic Counseling 
Program Director: Lori Erby, PhD, ScM, CGC 
Thesis: Illness Identity and Psychological Adaptation in Individuals with Hypermobile 
Ehlers Danlos Syndrome or Hypermobility Spectrum Disorder 
Thesis Advisors: William Klein, PhD and Lori Erby, PhD, ScM, CGC    
 
Thomas Jefferson University 
Philadelphia, PA        Aug 2009-May 2013  
Bachelor of Science in Pre-Medical Studies      
Program Director: Diana Cundell, PhD 
Minor Concentration in Genetics, Honors Program 
 
GENETIC COUNSELING ROTATION EXPERIENCE: 
Kennedy Krieger Institute 
Baltimore, MD        Oct 2019-Dec 2019 
Clinical Setting: Pediatric Neurodevelopment Disorders 
 
Children’s National Medical Center Rare Disease Institute 
Washington, DC        Sep 2019–Oct 2019 
Clinical Setting: Pediatric Oncology, Pediatric/General Genetics 
Case Presentation: Congenital Anomaly or Cystic Nephroma: Ruling Out DICER1 
 
National Institute of Allergy and Infectious Diseases, National Institutes of Health 
Bethesda, MD        Jun 2019–Aug 2019 
Clinical Research Setting: Multiple Sclerosis, Immunodeficiencies, Autoimmune Disorders 
 
Inova Cardiovascular Genomics Center / Pediatric Specialists of Virginia  
Fairfax-Falls Church, VA       Mar 2019–May 2019 
Clinical Setting: Cardiovascular Genetics, Pediatric/General Genetics 
 
National Cancer Institute, National Institutes of Health 
Bethesda, MD        Jan 2019–Mar 2019 
Clinical Research Setting: Hereditary Diffuse Gastric Cancer, Lung Cancer, Mesothelioma 
 
Johns Hopkins Institute of Genetic Medicine 
Baltimore, MD        Oct 2018–Dec 2018 
73 
 
Clinical Setting: Pediatric/General Genetics, Metabolism 
Medstar Washington Hospital Center, Cancer Institute 
Washington, DC        Sep 2018–Oct 2018 
Clinical Setting: Oncology  
 
Johns Hopkins Internal Medicine / Institute of Genetic Medicine 
Lutherville-Timonium, MD / Baltimore, MD    Jun 2018–Jul 2018 
Clinical Setting: Internal Medicine, Connective Tissue Disorders 
 
GeneDx 
Gaithersburg, MD       Mar 2018-May 2018 
Laboratory Setting 
Project & Presentation: Primary Ciliary Dyskinesia  
 
Greater Baltimore Medical Center Prenatal Diagnostic Center 
Towson, MD        Oct 2017-Mar 2018 
Clinical Setting: Prenatal Genetics 
 
RESEARCH EXPERIENCE:   
National Human Genome Research Institute, National Institutes of Health 
Social and Behavioral Research Branch 
Bethesda, MD        Oct 2015–Jul 2017 
 Post-Bac Research Fellow (Intramural Research Training Award) 
 Genetic Services Research Unit 
 Principal Investigator: Barbara Biesecker, PhD, MS 
• Analyze social and behavioral qualitative data for ClinSeq Exome Sequencing 
Study, POI RCT Consent Study, and CCGO Secondary Findings Analysis and 
Return Study 
• Maintain database, collect survey data, and return negative secondary findings in 
CCGO Secondary Findings Analysis and Return Study 
• Prepare and revise manuscripts for publication 
• Mentor and supervise summer college students conducting social and behavioral 
research 
 
 Genetic Counseling Training Program Coordinator  
 Johns Hopkins University / National Institutes of Health  
 Genetic Counseling Training Program 
 Program Director: Barbara Biesecker, PhD, MS 
• Provide administrative support for genetic counseling students and NIH faculty 
• Assist with genetic counseling student thesis research 
• Organize and participate in weekly Genetic Counseling Seminar course 
  
Thomas Jefferson University    
Philadelphia, PA        Aug 2012-May 2013  
 Student Researcher          
 Research Advisor: Frank Wilkinson, PhD 
74 
 
• Conduct research on polycomb-group proteins in drosophila and yeast 
• Learn and implement molecular biology techniques such as electrophoresis, real-
time PCR, and yeast two-hybrid assay 
 
PUBLICATIONS: 
Lewis KL, Heidlebaugh AR, Epps S, et al. Knowledge, motivations, expectations, and traits 
of an African, African-American, and Afro-Caribbean sequencing cohort and comparisons to 
the original ClinSeq® cohort. Genetics in Medicine, 2019;21(6):1355-62.  
 
Sapp JC, Johnston JJ, Driscoll K, Heidlebaugh AR, et al. Evaluation of Recipients of 
Positive and Negative Secondary Findings Evaluations in a Hybrid CLIA-Research 
Sequencing Pilot. American Journal of Human Genetics, 2018;103(3):358-66.  
 
Biesecker BB, Lewis KL, Umstead KL, Johnston JJ, Turbitt E, Fishler KP, Patton JH, Miller 
IM, Heidlebaugh AR, Biesecker LG. Web Platform vs In-Person Genetic Counselor for 
Return of Carrier Results From Exome Sequencing: A Randomized Clinical Trial. JAMA 
Internal Medicine, 2018;178(3):338-46.  
 
Turbitt E, Chrysostomou PP, Peay HL, Heidlebaugh AR, Nelson LM, Biesecker BB. A 
randomized controlled study of a consent intervention for participating in an NIH genome 
sequencing study. European Journal of Human Genetics 2018;26(5):622-30.  
 
Lawal TA, Lewis KL, Johnston JJ, Heidlebaugh AR, et al. Disclosure of cardiac variants of 
uncertain significance results in an exome cohort. Clinical Genetics, 2018;93(5):1022-29.  
 
POSTERS & PRESENTATIONS: 
Alexis Heidlebaugh, Joann Bodurtha, Christy Smith, Weiyi Mu, Debra Roter, Lori Erby & 
William Klein. Illness Identity and Psychological Adaptation in Individuals with 
Hypermobile Ehlers Danlos Syndrome or Hypermobility Spectrum Disorder. Poster. NHGRI 
Research Symposium, Bethesda, MD, November 2019.   
 
Alexis Heidlebaugh. Health Care Transition of Adolescents and Young Adults with Special 
Health Care Needs. Oral Presentation. NHGRI Post-Clinic Case Conference, Bethesda, MD, 
October 2019. 
 
Alexis Heidlebaugh. Facilitating Decision Making for Pregnant Women with Depression. 
Oral Presentation. NHGRI Post-Clinic Case Conference, Bethesda, MD, February 2018. 
 
Alexis Heidlebaugh. Recruiting African Americans, Africans, and Afro-Caribbeans to 
Participate in a Genome Sequencing Study: Lessons Learned. Oral Presentation. Social and 
Behavioral Research Branch Works-In Progress, Bethesda, MD, December 2016. 
 
Alexis R Heidlebaugh, Charlotte L Hepler, Katie L Lewis, Leslie G Biesecker, Barbara B 
Biesecker. Motivations for Participating in a Genome Sequencing Study: Views of African 
American, African, and Afro-Caribbean Participants. Poster. NHGRI Research Symposium, 




Heidlebaugh A, Wilkinson F. Positive Interactions among Pho, Psq, and dRybp. Poster. St. 
Joseph University Sigma Xi Student Research Symposium, Philadelphia PA, April 2013.  
 
Coia T, Heidlebaugh A, Moncada L, Pantalone L, Werdann A, Zapulla A, Shain R, 
Wilkinson F. An Undergraduate Exercise Incoporating IRB Approval for Genotypic Analysis 
of Phenylthiocarbamide Tasting. St. Joseph University Sigma Xi Student Research 




Rockville, MD        May 2016 – Jun 2017 
Hotline Call Specialist  
 
Olivia’s House Children’s Grief and Loss Center 
York, PA         Jul 2014 – Oct 2015 
Companion Volunteer 
 
Visiting Angels Living Assistance Services 
York, PA         Mar 2014 – Mar 2015 
Caregiving Professional for the Elderly and those with Disabilities 
 
TEACHING EXPERIENCE: 
York Suburban School District 
York, PA         Sep 2014-Jan 2015 
Middle School Science & Math Teaching Aide 
 
Thomas Jefferson University 
Philadelphia, PA        Aug 2010-May 2013 
Teaching Assistant, Academic Peer Tutor, Laboratory Course Preparation Student 
 
HONORS & AWARDS : 
Summa Cum Laude       May 2013 
Distinguished Honors Scholar      May 2013 
Academic Excellence in Pre-Medical Studies Preceptorship Award May 2013 
Gerda L and Frederick T Cundell Scholarship    Aug 2012-May 2013 
Academic and Faculty Scholarships for Academic Excellence  Aug 2009-May 2013 
 
PROFESSIONAL MEMBERSHIPS: 
Omicron Delta Kappa, National Leadership Society   Jan 2013-Present 
Alpha Lambda Delta, National Freshman Honor Society  Jan 2010-Present 
  
SERVICE: 
Leukemia and Lymphoma Society     Oct 2010-Oct 2015 
York, PA 




Servants, Inc        July 2014 
Red Lion, PA 
Missions Trip to Guatemala 
 
Thomas Jefferson University Asclepius Pre-Medical Studies Society 
Philadelphia, PA        Aug 2009-May 2013 
President, Member 
 
Thomas Jefferson University American Cancer Society Colleges Against Cancer and Relay 
for Life 
Philadelphia, PA        Jan 2010-May 2013 
Team Captain, Survivorship & Advocacy Committee Member 
 
